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Soft tissue sarcoma 
Soft tissue sarcomas are rare tumors, and globally account for less than 1% of all 
malignancies. They develop from the cells of the soft supporting tissues of the body (also 
known as mesenchyma): fat, muscles, nerves, fibrous tissues, blood and lymph vessels. 
Soft tissue sarcomas are therefore a heterogeneous group of tumors. They currently 
include more than 50 different histological subtypes. The classification of these tumors is 
complex and review of the histopathologic specimen by experienced pathologists is 
generally recommended for clinical practice and, a fortiori, for clinical research. Progress in 
the understanding of sarcoma has frequently resulted in identification of new histological 
subtypes or reclassification of existing ones. The development of immunochemistry, 
cytogenetic and molecular genetic has brought major progress in this field in the last 10 
years. The latest available classification of soft tissue tumors has been issued by the World 
Health Organization in 2002 [1]. 
Several histological grading systems have been proposed, with either 3 or 4 
classification levels. Most have been validated as prognostic factors for metastases free 
and overall survival in patients with untreated primary soft tissue sarcoma. The two most 
widely used grading systems are the one of the US National Cancer Institute (3 levels, 
based on the histological subtype, and corrected for tumor necrosis, mitotic rate, cellularity 
and/or pleomorphism for some subtypes), and the one of the French “Fédération Nationale 
des Centres de Lutte Contre le Cancer” (3 levels, based on tumor necrosis, mitotic rate and 
tumor differentiation, giving an equal weight to these 3 factors). The French system has 
been shown to better predict outcome, but both systems are still used. The two systems do 
overlap in approximately 2/3 of the cases [2]. 
Soft tissue sarcomas can occur in any site of the human body. According to the NCI 
webs site, almost half of them occur in extremities, 40% in trunk and retroperitoneum and 
10% in head and neck; more recently, the WHO has reported a slightly different distribution: 
75% are located in extremities, 10% in the trunk wall and 10% in the retroperitoneum. The 
two levels “CTOS code for anatomic site of disease” provides a standard classification 
system for the localization of the primary disease. 
Diagnosis and treatment of primary disease 
Soft tissue sarcomas are often diagnosed accidentally, because they generally develop 
without pain. Less than 1% of soft tissue tumors are malignant. Other soft tissue tumors are 
either benign or of intermediate malignancy (locally aggressive or rarely metastasizing), 
according to the last classification of soft tissue tumors [1]. The probability of malignancy of 
a newly diagnosed soft tissue tumor is related to size and depth, but, so far, malignancy 
can not be accurately predicted by clinical examinations and imaging techniques. A tumor 
biopsy is needed to confirm the histology, and this should preferably be performed in a 
specialized sarcoma center to avoid compromising the results of the subsequent surgery. 
Primary treatment consists of radical surgery, eventually associated to radiotherapy. 
Unfortunately, a large proportion of the patients will subsequently relapse locally or develop 
metastases. Adjuvant chemotherapy has not been proved to increase overall survival, but a 
meta-analysis or adjuvant trials has demonstrated a significant improvement of disease free 
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survival (10% at 5 years), both in terms of control of the local tumor (5% at 5 years) and of 
the metastatic spread (9% at 5 years) [3]. 
Advanced disease and clinical trials 
Inoperable locally advanced or metastatic disease at presentation, inoperable locoregional 
relapse and development of metastases are generally called “advanced disease”. 
Systemic therapy is used for patients with advanced disease. Although responses and 
prolongation of progression free survival have been observed, this therapeutic approach is 
generally considered as palliative. 
Cytotoxic agents that have demonstrated activity against soft tissue sarcoma are limited to 
doxorubicin, ifosfamide and dacarbazine. Multiple randomized clinical trials have been 
carried out to optimize the combination of these drugs as first treatment for advanced 
disease (generally called first line therapy). So far, no combination has been shown to 
significantly improve survival when compared to doxorubicin administered as a single agent 
at a dose of 75 or 80 mg/m2 every 3 weeks. 
Investigational new drugs are generally considered as therapeutic options after failure of 
the first line combination therapy. Most of the cytotoxic agents tested in the clinic against 
other malignancies have also been tested against soft tissue sarcoma in phase II trials, but 
none of them has showed any substantial activity in terms of objective response. 
Targeted therapies have recently brought new expectations for the treatment of soft tissue 
sarcoma. Mechanisms of carcinogenesis and tumor growth have been extensively studied 
for sarcoma, making them ideal candidates for targeted therapies. These expectations have 
been substantiated by the documentation of the activity of imatinib mesylate for Gastro-
Intestinal Stromal Tumors (GIST), a sarcoma entity that has been identified relatively 
recently and is known to be insensitive to chemotherapy. In a trial including 946 advanced 
GIST patients, the 2-years survival estimate is close to 70%, as compared to 20% with 
standard doxorubicin based chemotherapy [4]. The success of imatinib therapy for GIST is 
an encouraging example of the possibilities that can be offered by targeted therapies. 
Specific histological subtypes are, so far, rarely addressed in clinical trials, and are not 
even often used for stratification. The difficulty to conduct histology specific studies resides 
in the limited potential accrual (in a subgroup of a rare disease), associated to the 
complexity and constant evolution of the histopathological classification. Inclusion of this 
heterogeneous group of diseases in clinical trials may have restricted the discovery of new 
agents to “large spectrum” drugs active against most of the frequent histological subtypes. 
Additionally, the referral pattern of individual centers and even of clinical research groups 
may be largely affected by the quality of the collaboration between medical oncologists and 
organ specialists at the institutional level. This may lead to “selection biases” and 
irreproducible results in clinical trials. 
As an example, trials conducted in uterine leiomyosarcoma have shown a promising activity 
of the combination of docetaxel and gemcitabine, two agents that had failed “mixed 
histology” phase II studies [5]. 
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Objective response to therapy has been used to document activity of new drugs since the 
recommendation of the WHO in 1979. “Response” is defined as an objectively documented 
decrease in the size of cancer lesions (subsequent to the administration of the drug), which 
translates a biological activity of the drug. WHO response criteria may not have been an 
optimal screening tool for new drugs in sarcoma: they used a complex response evaluation 
algorithm that was often misunderstood or misinterpreted; they ignored modern imaging 
techniques like computerized tomographic scans and magnetic resonance imaging, both 
largely used for the staging of soft tissue sarcoma; more importantly, they are not 
appropriate to document the activity of cytostatic agents (expected to stop tumor growth) 
that do not necessarily result in an immediate decrease of the size of the lesions. A few 
active agents may have been missed because of the use of inappropriate criteria. 
Long disease stabilizations have been observed in recent phase II trials with trabectedin [6] 
and brostallicin [7], despite a limited number of objective responses. Both agents that are 
currently awaiting confirmation of their activity in controlled clinical trials.  
The Soft Tissue and Bone Sarcoma Group (STBSG) of the European Organization for 
Research and Treatment of Cancer (EORTC) has conducted multiple clinical trials in soft 
tissue sarcoma, with a particular focus on patients with advanced disease. Those trials data 
have all been managed at the EORTC Data Center, using similar data collection forms, and 
similar database formats. A central pathology review by a panel of experts is mandatory for 
all trials subjects. The group has consistently used the French grading system since its first 
publication. As results, the group has accumulated a database of over 2000 patients treated 
with first line therapy for advanced soft tissue sarcoma, 380 patients from phase II trials in 
second or third line therapy, and 946 advanced GIST patients treated with imatinib in the 
largest clinical trial conducted so far. 
Objectives of this thesis 
Prognostic factors for newly diagnosed sarcoma patients have extensively been studied. 
Histological grading systems have been specifically designed to estimate the patients’ 
survival from primary disease presentation. Host (age, sex, performance status, biological 
parameters at diagnosis) and disease factors (histological type, anatomical localization of 
the primary disease, tumor size, depth and spread) have been explored in univariate and 
multivariate analyses. A staging system based on both clinical and pathological factors has 
been proposed, and its prognostic value has been validated. Other prognostic indexes are 
available for specific subgroups (based on tumor respectability, anatomical localization, 
histological subtypes). 
None of this is available for patients with advanced disease treated with systemic therapy, 
and there are several reasons to believe that prognostic factors may be different in this 
population. Patients who reached the stage of advanced disease are an unfavorable 
selection of all patients with sarcoma. Prognostic factors at that time are expected to reflect 
both the natural course of the disease and the sensitivity to systemic therapy. Also, factors 
characterizing the previous evolution of the disease and the prior therapies need to be 
added to the list of variables that can affect the prognosis. 
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As only palliative treatments are available for advanced soft tissue sarcoma, there is an 
urgent need to explore new possible therapeutic options in well designed clinical trials. 
Targeted therapies are expected to play a major role in treatment of sarcoma in the future, 
but classical drug development methodology developed for cytotoxic drugs is probably not 
applicable to targeted therapies. A better understanding of the disease and of the factors 
likely to affect response to therapy would lead to optimization of the clinical trials designs, in 
terms of patients selection, stratification factors, selection of end-points for early drug 
development and historical references to assess the level or activity and toxicity of new 
agents. 
The difficulties linked to the complexity of the histology, to the use of different grading 
system, and, most of all, to the lack of large series of consistently documented cases have 
all been, so far, obstacle to address those issues in a consistent way. 
The EORTC prospectively obtained databases provided a unique opportunity to run 
retrospective analyses aiming at a better understanding of this complicated disease, and 
optimization of the design of future clinical trials that will be needed to improve the systemic 
therapy of these patients. This thesis describes part of this work. 
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Summary 
PURPOSE: A total of 2,185 patients with advanced soft tissue sarcomas who had been 
treated in seven clinical trials investigating the use of doxorubicin- or epirubicin-containing 
regimens as first-line chemotherapy were studied in this prognostic-factor analysis.  
PATIENTS AND METHODS: Overall survival time (median, 51 weeks) and response to 
chemotherapy (26% complete response or partial response) were the two end points. The 
cofactors were sex; age; performance status; prior therapies; the presence of locoregional 
or recurrent disease; lung, liver, and bone metastases at the time of entry onto the trial; long 
time period between the initial diagnosis of sarcoma and entry onto the study; and histologic 
type and grade.  
RESULTS: Univariate analyses showed (a) a significant, favorable influence of good 
performance status, young age, and absence of liver metastases on both survival time and 
response rate, (b) a significant, favorable influence of low histopathologic disease grade on 
survival time, despite a significantly lower response rate, (c) increased survival time for 
patients with a long time period between the initial diagnosis of sarcoma and entry onto the 
study, despite equivalent response rates, and (d) increased survival time with liposarcoma 
or synovial sarcoma, a decreased survival time with malignant fibrous histiocytoma, a lower 
response rate with leiomyosarcoma, and a higher response rate with liposarcoma (P < .05 
for all log-rank and 2 tests). The Cox model selected good performance status (P < .0001), 
absence of liver metastases (P = .0001), low histopathologic grade (P = .0002), long time 
lapse since initial diagnosis (P = .0004), and young age (P = .0045) as favorable prognostic 
factors of survival time. The logistic model selected absence of liver metastases (P < 
.0001), young age (P = .0024), high histopathologic grade (P = .0051), and liposarcoma (P 
= .0065) as favorable prognostic factors of response rate.  
CONCLUSION: This analysis demonstrates that for advanced soft tissue sarcoma, 
response to chemotherapy is not predicted by the same factors as is overall survival time. 
This needs to be taken into account in the interpretation of trials assessing the value of new 
agents for this disease on the basis of response to treatment.  
Introduction 
For more than 20 years, the Soft Tissue and Bone Sarcoma Group (STBSG) of the 
European Organization for Research and Treatment of Cancer (EORTC) has been 
investigating different chemotherapy regimens for advanced and metastatic soft tissue 
sarcomas. In chemotherapy-naive patients with advanced disease (who had either relapsed 
after primary tumor surgery and/or radiotherapy or presented with inoperable or metastatic 
disease), successive clinical trials were performed that investigated a series of doxorubicin- 
or epirubicin-containing regimens (Table 1). None of the randomized trials has 
demonstrated the superiority of any of the investigated regimens, either in terms of 
response to chemotherapy or in terms of survival [1-7]. The data from all trials have been 
managed at the EORTC Data Center, resulting in the accumulation of an homogeneous 
database for more than 2,000 prospectively recruited patients. This accumulation presented 
a unique opportunity to conduct a retrospective analysis of prognostic factors influencing 
response to chemotherapy and overall survival time. Although the prognosis of patients with 
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primary disease, as well as that of patients amenable to metastasectomy, had previously 
been studied, no data are currently available from large series to predict the duration of 
survival and probability of response to chemotherapy of patients with advanced disease. 
Table II-1: Therapeutic regimen 
Regimen Cycle description Cycle duration 
A Doxorubicin 75 mg/m2 3 weeks 
B 
Doxorubicin 50 mg/m2 
Ifosfamide 5 g/m2 
3 weeks 
C 
Doxorubicin 75 mg/m2 
Ifosfamide 5 g/m2 
GM-CSF 
3 weeks 
D Epirubicine 75 mg/m2 3 weeks 
E Epirubicine 150 mg/m2 3 weeks 
F Epirubicine 50 mg/m2, day 1-3 3 weeks 
G 
Doxorubicin 50 mg/m2 
Dacarbazine 250 mg/m2, day 1-5 
Cyclophosphamide 500 mg/m2 
Vincristine 1.5 mg/m2 
4 weeks 
H 
Doxorubicin 50 mg/m2 
Dacarbazine 250 mg/m2, day 1-5 
Cyclophosphamide 500 mg/m2, day 29 
Vincristine 1.5 mg/m2, day 29 
8 weeks 
I 
Doxorubicin 50 mg/m2 
Dacarbazine 750 mg/m2 
Cyclophosphamide 500 mg/m2 
Vincristine 1.5 mg/m2 
3 weeks 
 
Patients and methods 
Patients 
Patients who had been treated in seven studies investigating doxorubicin- or epirubicin-
containing regimens as a mode of first-line chemotherapy were included in this prognostic-
factor analysis. The therapeutic regimens are described in Table 1.  
End Points of the Analysis 
The two end points of our study were response to chemotherapy and overall survival time. 
The aim of the study was to determine whether the factors that influenced response to 
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chemotherapy were the same as the factors that influenced survival time and to build a set 
of independent prognostic factors for each end point.  
Survival time was computed from the date of randomization (in the randomized trials) or 
from the date of prospective registration (in the nonrandomized trials) to the date of death. 
Patients who were alive at the last follow-up date were censored.  
Response to chemotherapy was evaluated according to World Health Organization (WHO) 
criteria [8] in all trials. Complete responses and partial responses were externally reviewed 
and validated on the basis of source documents. Response to therapy was analyzed as a 
binary variable: patients who achieved a complete or partial response were considered 
"responders," and patients with stable disease or progression were considered "failures."  
Sample Size 
A total of 2,233 patients were registered in the seven trials. Patients were included in the 
analysis presented here regardless of their eligibility status for each particular trial. For 48 
patients, no follow-up data were available. Consequently, a total of 2,185 patients was 
included in the survival time analysis, and 446 patients were still alive at the time of their 
last follow-up. The analysis of response to chemotherapy included 1,922 cases. The 263 
remaining patients were not assessable for this end point.  
Investigated Cofactors 
The factors routinely recorded as baseline data in the different trials were investigated as 
potential prognostic factors (demographic data, history of sarcoma, extent of disease at the 
time of trial inclusion, and histology). The demographic variables included age, sex, and 
performance status before the start of chemotherapy. Age was recoded into four categories 
(< 40, 40 to 50, 50 to 60, and > 60 years). Performance status was measured on the WHO 
scale except for two trials in which it was retrospectively converted from the Karnofsky scale 
to the WHO scale. Variables related to the history of sarcoma included prior surgery and 
prior radiotherapy, as well as the time since the first diagnosis of sarcoma. This last variable 
was recoded into six categories (< 3, 3 to 6, 6 to 12, 12 to 24, 24 to 60, and > 60 months). 
Prior chemotherapy was an exclusion criterion in all trials.  
Data on the extent and localization of the disease included the presence of locoregional 
disease or local recurrence, as well as lung, liver, and bone metastases. Chest radiography, 
bone scans, and liver scans were mandatory at the time of entry onto all trials. Histologic 
subtype and histopathologic grade, as assessed by a panel of reference pathologists, were 
preferred over the use of local diagnosis, to ensure the consistency and homogeneity of the 
data. For practical reasons, only 70% of the cases could be reviewed. Analyses including 
these factors are therefore based on the subset of reviewed cases. Histologic subtypes 
were recoded as multiple binary variables.  
Statistical Methods 
All cofactors were first investigated as potential prognostic factors of survival and of 
response by univariate techniques. For survival time, the proportion of survivors was 
estimated by the Kaplan-Meier method [9] and the log-rank test was used for the 
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comparisons [10]. For ordered categorical variables (age group, performance status, 
histopathologic grade, time since initial diagnosis), the log-rank test for trend was used. The 
proportion of responders was estimated in contingency tables, and the categories were 
compared using the 2 test. For ordered categorical variables, the 2 test for trend was 
used [11]. Two multivariate models were built: a Cox model [12] for overall survival time, 
and a logistic model [13] for response to chemotherapy. All factors that presented with a 
significant or borderline prognostic value in the univariate analyses were initially included in 
the models. Nonsignificant factors were subsequently removed according to a backward 
selection procedure.  
The results presented in this article are based on unadjusted analyses of categorical 
variables. The final multivariate models were later adjusted by therapeutic regimen and by 
study, which did not change any conclusion. Replacement of categorized variables by 
original continuous variables (age, time lapse since diagnosis) also did not change any 
conclusion.  
Results 
In the series of 2,185 patients with follow-up data, the median survival time was 51 weeks. 
The overall survival time for all patients is shown in Fig 1. Survival curves for the therapeutic 
arms of the different studies were all superimposable. Comparison of the therapeutic arms 
in all randomized trials showed no significant differences (Table 2).  
 
Figure II-1:  
Overall survival 
O, observed failures;  
N, number of patients 
 
In the series of 1,922 patients who were assessable for response, an overall response rate 
of 26% was observed. This response rate varied largely from one study to the other, but, 
with the exception of one study, no statistically significant difference was observed between 
the randomized therapeutic arms in any of the studies (Table 2). These findings are in 
agreement with the individual study results from the original publications, which were based 
on eligible patients [1-7]. 
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Table II-2: Results of previous studies 
Study 
no. 
Treat. 
Arm 
No of 
cases 
No eval. 
survival 
No eval. 
resp. 
Resp.  
rate 
Median 
surv. 
P-values: 
resp / surv 
G 191 184 151 34% 44 wks 
62861 
H 121 118 93 15% 42 wks 
P = 0.001 / 
P = 0.422 
A 106 101 85 25% 41 wks 
62801 
D 104 102 84 18% 46 wks 
P = 0.277 /  
P = 0.622 
62842 B 203 195 177 34% 58 wks  
A 295 289 266 23% 49 wks 
B 297 287 254 28% 57 wks 62851 
I 157 157 146 27% 51 wks 
P = 0.437 /  
P = 0.896 
62883 C 111 111 99 46% 54 wks  
A 112 111 99 13% 50 wks 
E 111 109 97 16% 48 wks 62901 
F 111 109 93 17% 45 wks 
P = 0.705 /  
P = 0.967 
B 157 155 145 23% 55 wks 
62903 
C 157 157 133 26% 49 wks 
P = 0.491 /  
P = 0.919 
TOTAL  2233 2185 1922 26% 51 wks  
wks, weeks; eval., evaluable; resp., response; surv., survival 
Univariate Analysis of Survival Time 
The univariate analysis of survival time (Table 3) demonstrated a highly significant favorable 
prognostic value of young age, good performance status, absence of liver and bone 
metastases, low histopathologic grade, and long time lapse since the initial diagnosis of 
sarcoma. Patients with liposarcoma and those with synovial sarcoma had a significantly 
better survival time, whereas patients with malignant fibrous histiocytoma had a significantly 
worse survival time. The other investigated cofactors did not affect survival time. 
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Table II-3: Univariate analysis of survival time 
  
No of 
cases 
No of 
death 
1-yr 
surviv. 
estim. 
2-yr 
surviv. 
estim. 
Median 
survival 
time 
P 
Overall  2185 1739 48% 22% 51 wks - 
< 40 yrs 562 430 53% 24% 56 wks 
40 - 50 yrs 434 354 52% 23% 55 wks 
50 - 60 yrs 571 459 48% 22% 50 wks 
Age group 
> 60 yrs 564 446 39% 20% 41 wks 
<0.001 
PS 0 894 672 59% 30% 65 wks 
PS 1 802 657 47% 19% 49 wks 
PS 2 375 324 26% 9% 27 wks 
Performance 
status 
PS 3 25 22 10% - 9 wks 
<0.0001 
No 1637 1286 50% 24% 52 wks Liver 
metastases Yes 372 314 42% 13% 44 wks 
<0.0001 
No 976 772 48% 24% 50 wks Lung 
metastases Yes 1159 932 48% 20% 51 wks 
0.682 
No 1715 1370 49% 23% 52 wks Bone 
metastases Yes 222 174 39% 14% 41 wks 
0.0023 
Leiomyos. 538 449 49% 20% 52 wks 0.438 
MFH 218 181 39% 18% 42 wks 0.012 
Synovial 120 92 67% 26% 69 wks 0.011 
Liposarc. 111 86 70% 37% 76 wks 0.0005 
Fibrosarc. 69 56 43% 18% 49 wks 0.591 
Histologic  
subtype 
Other 506 403 40% 22% 42 wks 0.298 
I 176 122 64% 40% 79 wks 
II 457 377 52% 22% 54 wks 
Tumor 
grade 
III 728 606 42% 17% 44 wks 
<0.0001 
< 3 mon 397 311 44% 21% 45 wks 
3-6 mon 146 116 34% 15% 36 wks 
6-12 mon 253 216 36% 10% 37 wks 
1-2 yrs 207 166 48% 18% 51 wks 
2-5 yrs 207 147 62% 34% 71 wks 
Time since 
initial diagnosis 
of sarcoma 
> 5 yrs 96 64 66% 34% 82 wks 
<0.0001 
yr, year; surviv.estim., survival estimate 
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 Multivariate Analysis of Survival Time 
The final Cox model for overall survival time is described in Table 4. According to this 
model, good performance status (P < .0001), absence of liver metastases (P < .0001), low 
histopathologic grade (P = .0002), long time lapse since the first diagnosis of sarcoma (long 
disease-free interval) (P = .0004), and young age (P = .0045) were the only independent 
favorable prognostic factors of survival time.  
Table II-4: Final Cox model for overall survival 
Factor Parameter estimate Risk ratio P-value 
Performance status 0.415 1.515 < 0.0001 
Liver involvement 0.379 1.461 < 0.0001 
Tumor grade 0.215 1.240 0.0002 
Delay since initial diagnosis of sarcoma - 0.082 0.921 0.0004 
Age 0.102 1.107 0.0045 
 
The impact of each factor may be quantified by the increase in the "hazard ratio" 
(immediate risk of death) of two successive patient categories (ie, in performance status, 
PS 1 compared with PS 0). According to the final Cox model, this risk increased by 51.5% 
for performance status categories, 46.1% for liver involvement, 24% for histopathologic 
grade categories, and 10.7% for age categories and decreased by 7.9% for elapsed time 
categories.  
The liposarcoma and malignant fibrous histiocytoma categories dropped out of the 
multivariate models when tumor grade was included. Indeed, these factors are correlated. 
The overall series included 13% of grade 1 tumors, 34% of grade 2 tumors, and 53% of 
grade 3 tumors. For liposarcoma, these figures were 39%, 34%, and 28%, respectively. For 
malignant fibrous histiocytoma, these figures were 8%, 24%, and 68%, respectively.  
The synovial sarcoma category included only 1% of patients with liver involvement (v 19% 
in other histologic categories and 14% if the leiomyosarcoma category is excluded), as well 
as a high proportion (58%) of patients under 40 years of age (v 25% in other histologic 
categories). This factor dropped out of the final model, which included age and liver 
involvement. The overall survival for all independent prognostic subgroups is shown in 
Figures 2 through 7. 
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Figure II-2:  
Overall survival by age group 
O, observed failures;  
N, total number of patients 
 
 
 
Figure II-3:  
Overall survival by performance 
status 
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Overall survival by liver 
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Figure II-5:  
Overall survival by 
histopathological grade 
 
 
 
Figure II-6:  
Overall survival by histologic 
cell type 
Leio, leiomyosarcoma; 
MFH, malignant fibrous histiocytoma; 
Synov, synovial sarcoma; 
Lipo, liposarcoma; 
Fibro, fibrosarcoma 
 
 
Figure II-7:  
Overall survival by time elapsed 
since initial diagnosis of 
sarcoma 
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Table II-5: Univariate analysis of response to chemotherapy 
  No of cases 
No of 
responders 
Response rate P 
Overall  2185 1739 48% - 
< 40 yrs 562 430 53% 
40 - 50 yrs 434 354 52% 
50 - 60 yrs 571 459 48% 
Age group 
> 60 yrs 564 446 39% 
0.001 
PS 0 894 672 59% 
PS 1 802 657 47% 
PS 2 375 324 26% 
Performance 
status 
PS 3 25 22 10% 
0.001 
No 1637 1286 50% Liver 
metast Yes 372 314 42% 
0.001 
No 976 772 48% Lung 
metastases Yes 1159 932 48% 
0.021 
No 1715 1370 49% Bone 
metastases Yes 222 174 39% 
0.109 
Leiomyos. 538 449 49% 0.002 
MFH 218 181 39% 0.716 
Synovial 120 92 67% 0.313 
Liposarc. 111 86 70% 0.049 
Fibrosarc. 69 56 43% 0.394 
Histologic  
subtype 
Other 506 403 40% 0.038 
I 176 122 64% 
II 457 377 52% 
Tumor 
grade 
III 728 606 42% 
0.008 
< 3 mon 397 311 44% 
3-6 mon 146 116 34% 
6-12 mon 253 216 36% 
1-2 yrs 207 166 48% 
2-5 yrs 207 147 62% 
Time since 
initial diagnosis 
of sarcoma 
> 5 yrs 96 64 66% 
0.495 
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Univariate Analysis of Response Rate 
The results of the univariate analysis of response rate (Table 5) demonstrated a highly 
significant favorable prognostic value for the absence of liver metastases, young age, and 
good performance status. The response rates were also significantly higher for high-grade 
tumors and lower for leiomyosarcoma. The higher response rate of patients with lung 
metastases and those with liposarcoma is of borderline significance. 
Multivariate Analysis of Response Rate 
The final logistic model for response to chemotherapy is described in Table 6. According to 
this model, absence of liver lesions (P < .0001), young age (P = .0024), high 
histopathologic grade (P = .0051), and liposarcoma (P = .065) were the only independent 
favorable prognostic factors of response. The leiomyosarcoma category dropped out of the 
logistic model when liver involvement was included. In patients with liver lesions, 
leiomyosarcoma accounted for 62% of the cases; 11% of responses were observed versus 
20% for other histologic categories. In patients without liver lesions, leiomyosarcoma only 
represented 29% of the cases, with a response rate of 29%, compared with 32% in other 
histologies. Performance status also dropped out of the final model. 
Table II-6: Final logistic model for response to chemotherapy 
Factor Parameter estimate Odds ratio P-value 
Liver involvement 0.963 2.620 < 0.0001 
Age 0.184 1.202 0.0024 
Tumor grade - 0.297 0.743 0.0051 
Liposarcoma - 0.673 0.510 0.0065 
(intercept) 1.202   
 
Discussion 
Identification of prognostic factors in soft tissue sarcoma has been a field of extensive 
research in this rare group of malignant diseases, but it was primarily limited to the 
definition of staging systems for patients presenting for the first time with this disease [14-
26]. The staging systems used in these analyses were usually based on a combination of 
clinical and histopathologic factors. Universally agreed-upon clinical prognostic factors 
include tumor size and quality of surgery (which obviously depends on tumor localization), 
whereas proposed histopathologic grading systems are usually based on mitotic count, 
tumor necrosis, and degree of differentiation [14]. In most of the studies, histopathologic 
grade was the most important prognostic factor, but Gaynor et al [20] also demonstrated 
that the prognostic value of this factor disappeared beyond 18 months. On behalf of the 
EORTC–Soft Tissue and Bone Sarcoma Group, van Unnik et al [14] have proposed a 
prognostic index, which is based on tumor size, mitotic count, and necrosis.  
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The prognostic factors for patients presenting with inoperable or metastatic disease and for 
patients developing metastases after surgery and/or radiotherapy may be different. So far, 
the prognostic factors for advanced and recurring cases have only been studied in the 
highly select population of patients amenable to metastasectomy [27-30]. In patients with 
advanced sarcomas who were not candidates for surgery, some data are available from 
studies that investigated specific chemotherapy regimens [1,31-33] but no large-scale 
analysis has been conducted so far. Our unique series of over 2,000 patients has been 
used to provide a model that predicts the probability of response to chemotherapy and the 
overall survival time in this population.  
Despite the fact that age and performance status are generally not reported as prognostic 
factors for patients with primary disease, it is not surprising that these factors correlate with 
survival time in patients with advanced disease. This was also reported by Borden et al.31 In 
our study, we have also demonstrated that age is highly predictive for response to first-line 
chemotherapy, but performance status does not add predictive information to the model. 
The absence of significant prognostic value for factors related to the nature and extent of 
previous therapy suggests that once a patient presents with inoperable advanced soft tissue 
sarcoma, prior modes of therapy do not have any further impact on the outcome.  
Liver metastases had a very significant adverse predictive value for both response and 
survival. This might be explained by two hypotheses: (1) liver metastases are a sign of 
advanced disease, which explains the poor prognosis of those patients, or (2) the presence 
of liver metastases in itself is a poor prognostic factor, regardless of the degree of 
advancement of the disease, because liver metastases are apparently less chemosensitive 
than other lesions [33]. Both hypotheses need to be explored further.  
Patients with a long time lapse since the first diagnosis of sarcoma had a better survival 
time than did patients recently diagnosed. This has also been reported with regard to other 
types of tumors, for which a long previous "disease-free survival" predicts a long survival 
time when patients relapse. Patients with a high histopathologic grade of disease had a 
significantly worse survival time than did the others, despite a significantly higher response 
rate. This is compatible with the recognition that high-grade tumors are more 
chemosensitive, but responses tend to be of short duration in these patients and are often 
followed by rapid progression.  
The univariate analysis demonstrated the prognostic importance of histologic subtype. 
Patients with liposarcoma and synovial sarcoma had a significantly better survival time than 
did patients with other cell types, whereas patients with malignant fibrous histiocytoma had 
a worse survival time. Liposarcoma patients had a higher response rate, and 
leiomyosarcoma patients had a lower response rate. According to our analysis, liposarcoma 
appears in the form of chemosensitive tumors with a good prognosis of survival. The 
distribution of tumor grades in this histologic subtype explains the favorable survival time 
but is in contrast with the high response rate. Other histopathologic variables dropped out of 
the multivariate models, but the analysis presented here clarifies these findings on the basis 
of their correlation with other prognostic factors.  
The lower probability of response to chemotherapy in leiomyosarcoma patients, which is in 
contrast with previously reported data [31,33] is linked to the increased frequency of liver 
metastases in these patients. Correlation of these two factors could be a result of the high 
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proportion of abdominal leiomyosarcoma cases in our series, which have a greater 
propensity for liver metastases. Because our data are up to 20 years old, the histologic 
entity of "gastrointestinal stromal sarcoma" had not been identified at the time of diagnosis 
of most of these patients, and these cases are probably included as leiomyosarcomas in 
our series. Unfortunately, we have not systematically recorded the site of origin of sarcoma 
in all trials and therefore cannot confirm this hypothesis. More recent data will enable us to 
study this issue further.  
The decreased survival time in cases of malignant fibrous histiocytoma is obviously linked 
to the distribution of the histopathologic grades of these tumors. Synovial sarcoma usually 
involves young patients without liver metastases, which explains their good survival time. 
Finally, the overall survival time curve shows that a small proportion of patients is still 
surviving after 5 years and suggests that some of these patients may have been cured by 
chemotherapy.  
In conclusion, this analysis demonstrates that for advanced soft tissue sarcomas, the 
probability of achieving response to chemotherapy is not predicted by the same factors as 
in overall survival time. While young age and the absence of liver metastases significantly 
affect both end points in a favorable way, low histopathologic grade has a favorable impact 
on survival time and an adverse impact on response rate. This should be taken into account 
in the interpretation of trials of new therapeutic agents in which the activity results are based 
on response.  
The study also demonstrates the prognostic value of histologic subtypes of sarcoma. So far, 
we have been unable to confirm whether these factors add independent prognostic 
information to the described models, except for cases of liposarcoma, but we could 
demonstrate why they affected overall survival time and response to chemotherapy. Further 
investigations of the correlation between the histologic subtype, the site of origin of the 
disease, and the sites of the metastases should provide a better understanding of the 
behavior of the different histologic subtypes. 
Author update (2002) 
This analysis of a large database of patients with advanced soft tissue sarcoma documents 
the (expected) adverse prognosis of patients with old age or poor performance status, and, 
more interestingly, of patients with liver metastases. 
This last finding could be explained by 3 hypotheses: 
• liver metastases per se have a poor chemosensitivity (to anthracycline containing 
regimen), 
• the presence of liver metastases is an indicator of advanced disease, 
• patients with Gastro-Intestinal Stromal Tumors (GIST) in our population could have 
been entirely responsible for the apparent adverse prognostic value of liver 
metastases. 
In order to explore the last hypothesis further, we have succeeded in identifying the site of 
the original tumor in 58 % of the patients and have subsequently been able to isolate a sub-
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population of 1249 patients that does not include GIST cases. This sub-population excludes 
patients with tumors of gastro-intestinal, abdominal or unknown origin, who had either been 
classified by the review panel as "leiomyosarcoma" or "miscellaneous sarcoma", or had not 
been externally reviewed. 
In this sub-population, the presence of liver metastases remains a significant prognostic 
factor, both in the univariate and multivariate analyses (table 1). This demonstrates that our 
original findings were not entirely due to the confounding effect of GIST cases, and that the 
two first hypotheses remain worth investigating. 
Leiomyosarcoma from this sub-population originate mainly from the gynecological tract 
(58%) or the extremities (25%). Their response rate (28%) does not differ significantly 
(P=0.42, chi-square test) from the response rate in other cell types (30%). This is in 
contrast with the total population, where the low response rate of "leiomyosarcoma" is 
probably linked to the high proportion of abdominal and gastro-intestinal tumors and of liver 
metastases, as suggested in the discussion. 
The original univariate analysis also highlights differences in response rate and survival 
between histologic subtypes. This variable is correlated with other prognostic factors and 
drops out of the multivariate models. However, as new therapeutic approaches in soft tissue 
sarcoma are targeting specific histologic subtypes, this paper, added to the more recent 
publication of progression free rates [34], provides useful historical data for early drug 
development. 
Table II-7: Prognostic value of liver involvement 
Parameter  Survival Response 
Analysis  Univariate Multivariate Univariate Multivariate 
Hazard / Odds ratio 1.374 1.450 3.236 2.899 Original series 
(updated data) P-value < 0.0001 < 0.0001 < 0.0001 < 0.0001 
Hazard / Odds ratio 1.312 1.412 1.807 1.792 Sub-population 
excluding possible 
GIST cases P-value 0.0082 0.0079 0.0178 0.0226 
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Abstract 
Adult patients with metastatic or locally advanced irresectable soft-tissue sarcoma (ASTS) 
are generally considered as incurable. Whether some of these patients achieve long-term 
survival after first-line treatment with chemotherapy is not known. Patients with ASTS still 
alive 5 years after initial treatment with a doxorubicin-containing regimen, i.e. long-term 
survivors, were analysed among the 2187 patients included in first-line chemotherapy 
protocols between 1976 and 1990 in seven trials of the European Organization for 
Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 
STBSG) group. 1888 patients were followed for at least 5 years. The initial clinical 
characteristics and the outcome of the long-term survivors were investigated. 66 of the 
1888 patients were alive at 5 years and the projected 5-year survival was 8% in this series. 
Age or histological subtypes were similar in the long-term survivors compared with the other 
patients. The percentages of females (69%), of grade 1 tumours (35%), of patients with an 
initial performance status (PS) of 0 (63%) were significantly higher in the long-term 
survivors while liver metastasis (6% versus 21%) were significantly less frequent. Long-term 
survivors were observed in all subgroups of patients. 31, 31, 31 and 6% of the long-term 
survivors were in complete response (CR), partial response (PR), stable disease (SD), and 
progressive disease (PD), respectively, after the first-line regimen. A CR to a doxorubicin-
containing regimen was the major parameter correlated to 5-year survival. In multivariate 
analysis using a logistic model, independent parameters correlated to 5-year survival were 
PS, female gender, grade I tumours, and the achievement of a CR after first-line treatment, 
which was retained as the most powerful predictor for 5-year survival. 10 of the 66 patients 
died after 5 years in this series, including 8 patients in PD or SD after first-line treatment 
versus 2 patients in PR or CR (P=0.01). 8% of patients with ASTS are alive 5 years after 
first-line chemotherapy with a doxorubicin-containing regimen. Long-term survivors are 
observed in all prognostic subgroups of patients, in particular those achieving a CR to first-
line chemotherapy.  
Introduction 
The prognosis of patients with irresectable or advanced metastatic soft-tissue sarcoma 
(ASTS) remains poor with response rates to chemotherapy ranging from 20–35% in most 
series and a median survival of at best 12 months [1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11]. The 
treatment of ASTS is therefore generally considered as palliative. However, long-term 
survival can be achieved in patients with metastatic sarcoma in whom complete remission 
is achieved after complete resection of all metastases [12 and 13], as well as in patients 
with locally advanced disease when adequate surgery is rendered possible by preoperative 
chemotherapy [14]. However, whether long-term survival can be achieved in patients with 
irresectable metastatic or advanced sarcoma treated with chemotherapy has seldom been 
addressed in a large prospective series of ASTS [15]. If long-term survival can be achieved 
in some patients with ASTS treated with chemotherapy, the therapeutic strategy may be 
significantly modified for subsets of patients.  
The objectives of this study were to evaluate the frequency and the clinical characteristics 
of long-term survivors in patients with ASTS. With this aim, we performed a retrospective 
study of long-term survivors in a database of 2187 patients treated with a doxorubicin-
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containing regimen between 1976 and 1990 in trials carried out by the European 
Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group 
(EORTC STBSG) [2, 3, 4, 5, 6, 7 and 8].  
Patients and methods 
Database 
This study was performed retrospectively using a database involving 2187 patients ASTS, 
treated with a doxorubicin-containing regimen as first-line chemotherapy, within 7 
prospective EORTC STBSG studies between 1976 and 1990 [1, 2, 3, 4, 5, 6, 7 and 8] 
(Table 1). Of these 2187 patients, 1888 (86%) had a minimum follow-up of 5 years since 
the initiation of chemotherapy: 66 were alive at 5 years, and 1822 had died within the first 5 
years. The chemotherapy regimens used in these studies were: doxorubicin single agent [2, 
4 and 6], epirubicin single agent [2 and 6], doxorubicin and ifosfamide combinations [3, 4, 7 
and 8], doxorubicin, vincristine, cyclophosphamide, dacarbazine (DTIC) combinations [1 
and 4]; doses and schedules were previously reported [1, 2, 3, 4, 5, 6, 7 and 8]. Survival 
was not significantly different between the arms of the randomised studies. Inclusion and 
exclusion criteria in these seven trials were similar: patients with locally advanced 
irresectable ASTS and/or distant metastasis, aged between 15 and 75 years, with evidence 
of tumour progression within 2 months were included. The following tumour cell types were 
included: malignant fibrous histiocytoma (MFH), liposarcoma, rhabdomyosarcoma, synovial 
sarcoma, malignant paraganglioma, fibrosarcoma, leiomyosarcoma, angiosarcoma, 
haemangiopericytoma, neurogenic sarcoma, unclassified sarcoma, miscellaneous sarcoma 
including mixed mesodermal tumours of the uterus. Malignant mesothelioma, 
chondrosarcoma, neuroblastoma, osteosarcoma, Ewing's sarcoma, embryonal 
rhabdomyosarcoma were not included. Major exclusion criteria included a previous history 
of cardiovascular disease, renal failure, symptomatic or known Central Nervous System 
(CNS) metastases, abnormal serum bilirubin, and second primary malignant tumours 
(except adequately treated in situ carcinoma of cervix or basal cell carcinoma). 
Analysis 
The proportion of patients surviving at 5 years, their clinical characteristics at inclusion, their 
response to first-line treatment and their outcome beyond 5 years were investigated. These 
characteristics were compared with those of patients who died within 5 years after inclusion 
in the trial. Patients lost to follow-up within 5 years of inclusion were not considered in this 
analysis.  
Statistics 
The clinical characteristics of the patients were compared using the Chi square test or 
Fisher's Exact test for binary variables, the overall Chi-square test for categorical non-
ordered variables and the Mantel and Haenszel Chi-square test for ordered categorical 
variables. Survival curves were plotted according to the method of Kaplan–Meier. Survival 
curves were compared using the log-rank test. Multivariate analysis of parameters 
correlated with 5-year survival was performed using a logistic regression model.  
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Results 
The median overall survival of the series of 2187 patients was 354 days (11.7 months). 355 
patients were still alive in October 2000. The survival estimate was 8% at 5 years, 7.6% at 6 
years, 6.8% at 7 years and 5.6% at 8 years (standard error <1%). No deaths were recorded 
beyond 8 years; 9- and 10-year survival estimates were therefore also 5.6%. Among the 66 
patients alive at 5 years, 10 died beyond 5 years after inclusion. The 6-, 7- and 8-year 
survival estimates for 5-year survivors were 94, 85 and 70%, respectively (Fig. 1). 
Parameters correlated to 5-year survival 
The follow-up of 299 patients was shorter than 5 years: these patients were not included in 
any further analyses. Parameters correlated to 5-year survival were therefore analysed in 
1888 patients. The characteristics of the 66 patients alive at 5 years were compared with 
those of the 1822 patients who died within 5 years after registration (Table 1). 69% of 5-
year survivors were females and 31% males (P=0.004). Age was not significantly different 
in the two groups. The proportion of patients with PS of 0 was significantly higher in the 5-
year survivors compared with the remaining patients (63% versus 41%) (P=0.002). Five-
year survivors more frequently had grade 1 tumours (35% versus 11%), and less frequently 
grade 3 tumours (38% versus 55%) (P<0.001) (Table 1). There were also significantly less 
liver metastases (6% versus 21%) in the 5-year survivors compared with other patients 
(P=0.003). In contrast, histological subtypes were not significantly different in the 5-year 
survivors compared with patients who died before 5 years (Table 1). Using a multivariate 
analysis with logistic regression, parameters (excluding response to chemotherapy) 
independently correlated to a poor 5-year survival rate were similar to those previously 
identified as independent prognostic variables for overall survival in the same series: male 
sex (Relative Risk RR: 2.1), higher tumour grade (RR: 2.3), liver metastases (RR: 4.5) and 
worse performance status (RR: 2.7) (data not shown). However, 5-year survivors were 
observed in all prognostic subgroups in this series ( Table 1). 
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Figure III-1: Overall survival  
a)in the whole series of 2187 
patients;  
b)after 5 years in the 66 patients 
alive after 5 years;  
c)after 5 years in patients in CR, 
PR, NC and PD after first line 
therapy. 
O, observed deaths,  
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Table III-1: Clinical characteristics of 5 years survivors 
Characteristics  
5-years survivors 
N (%) 
Others 
N (%) P-value 
Male 22 (33) 887 (49) 
Gender 
Female 44 (67) 906 (51) 
0.004 
< 40 22 (34) 858 (26) 
40 – 50 13 (20) 368 (21) 
50 – 60 17 (26) 477 (27) 
Age (years) 
> 60 13 (20) 468 (26) 
0.13 
I 14 (35) 129 (11) 
II 11 (28) 389 (33) Tumor grade 
III 15 (38) 644 (55) 
< 0.001 
0 40 (63) 720 (41) 
1 19 (30) 779 (45) 
2 5 (8) 243 (14) 
PS 
3 0 (0) 3 (0.2) 
0.002 
Locally advanced 27 (44) 342 (20) 
Metastatic 28 (46) 1142 (68) Disease 
Both 6 (10) 190 (11) 
0.005 
No 33 (52) 774 (45) 
Lung metastases 
Yes 30 (48) 962 (55) 
0.24 
Yes 4 (6) 326 (21) 
Liver metastases 
No 59 (94) 1236 (79) 
0.003 
MFH 6 (14) 185 (14) 
Fibrosarcoma 2 (5) 57 (4) 
Liposarcoma 3 (7) 92 (7) 
Leiomyosarcoma 13 (31) 471 (36) 
Synovialosarcoma 2 (5) 95 (7) 
Neurosarcoma 4 (10) 96 (7) 
Histology 
Others 12 (29) 316 (24) 
0.946 
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Characteristics  
5-years survivors 
N (%) 
Others 
N (%) P-value 
62761 [2] 7 (3) 265 (97) 
62801 [3] 0 (0) 168 (100) 
62842 [4] 0 (0) 142 (100) 
62851 [5] 44 (7) 596 (93) 
62883 [6] 3 (3) 102 (97) 
62901 [7] 5 (2) 277 (98) 
Study [reference] 
62903 [8] 7 (3) 272 (97) 
 
Response to first-line chemotherapy and 5-year survival 
Among the 66 patients with ASTS alive at 5 years, 17 (31%) had experienced complete 
response (CR) and 17 (31%) partial response (PR) to first-line chemotherapy, respectively 
(Table 2). This proportion was significantly higher than in other patients (P<10−5). In 
addition, 17 (31%) of 5-year survivors had stable disease (SD) as their best response to 
first-line treatment and 3 (6%) had progressive disease (PD). The contribution of 
subsequent treatment cannot be assessed since it was not documented in the database 
(Table 2). When CR to first-line chemotherapy was introduced in the multivariate model, CR 
was found to be the most potent prognostic factor for 5-year survival (Table 3). However, 
here also, 5-year survival was observed in all subgroups, even in patients whose best 
response was PD after a first-line regimen containing doxorubicin. Of note, response to 
first-line chemotherapy still strongly influenced the outcome of these patients after 5 years: 
2 of 3 patients with PD died between 5 and 7 years, compared with 6 of 17 patients in 
stable disease and 1 of 17 both for PR and CR patients (Fig. 1c, P=0.01). 
Table III-2: Response to first line doxorubicin-containing regimen 
Response  
to 1st line 
5-years survivors 
(n=66) 
Others 
(n=1822) P-value 
% of 5 years 
survivors amongst 
response subgroup 
CR 17 (31%) 64 (4%)  17 / 81 (21%) 
PR 17 (31%) 306 (19%)  17 / 323 (5%) 
NC 17 (31%) 641 (39%)  17 / 658 (3%) 
PD 3 (6%) 627 (38%) 0.00001 3 / 630 (0.5%) 
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Table III-3: Multivariate analysis of prognostic factors for 5-years survival 
Variable 
Parameter 
estimate 
Standard 
error 
Wald  
chi-
square 
P-value 
Odds 
ratio 
95% 
confidence 
interval 
Intercept 2.8555 0.8128 12.3408 0.0004   
PS 0.7052 0.3113 5.1314 0.0235 2.024 1.08-3.74) 
Grade 0.7790 0.2353 10.9625 0.0009 2.179 (1.36-3.52) 
Female gender -0.8286 0.3798 4.7589 0.0291 0.437 (0.30-0.93) 
CR to 1st line -2.1505 0.4634 21.5363 0.0001 0.116 (0.40-0.29) 
 
Discussion 
These results show that ASTS is not an incurable disease: 8% of these patients are alive 5 
years after initial diagnosis, and the majority of them experience long-term survival 
afterwards. Several clinical parameters, such as gender, PS, tumour grade and liver 
metastasis were found to be correlated to 5-year survival in univariate and multivariate 
analysis, and independent prognostic factors for 5-year survival were actually similar to 
those correlated to overall survival since the inclusion in the trial within the same series [1]. 
However, the histological subtype, an important prognostic factor for overall survival during 
the first 5 years actually lost its predictive value afterwards and was found not to 
significantly influence 5-year survival in this study. This is likely to be related to the slower 
progression rate in liposarcomas compared with other sarcomas in patients with advanced 
disease within the first years; however, eventually a similar proportion of patient with 
liposarcoma relapse and die of their disease, compared with patients with other sarcoma 
subtypes. An important observation from this series is that 5-year survivors were observed 
in all subgroups of patients, even in those with high grade tumours, liver or bone 
metastasis, and poor performance status.  
Clinical response to first-line regimen was found to be the most significant parameter 
correlated to 5-year survival. Actually, a major difference was observed between patients 
who achieved CR, and patients who achieved PR, SD, or PD, with a 21% (17/81) rate of 5-
year survival for the former, compared with a 5% rate for the latter. Interestingly, the 
percentage of long-term survivors among patients who achieve CR following treatment with 
a first-line regimen in this series is very similar to that of other published series in which CR 
was achieved by other means, including surgery, or surgery plus chemotherapy. This 
percentage ranged between 20 and 30% in the surgical series reported by Putnam and 
colleagues [12], in a series of a combination of chemotherapy and surgery [13], in a series 
of patients treated with chemotherapy only reported by Yap and colleagues [15], and with 
high-dose chemotherapy in a series where this unusual strategy was tested [16, 17, 18, 19, 
20 and 21].  
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It should be noted that the majority of long-term survivors did not achieve CR after first-line 
chemotherapy. It is likely that these patients have been proposed for second-line 
chemotherapy or resection of metastases sites. However, the second-line treatment was 
not documented in the database, and the contribution of these treatments to the favourable 
outcome of these patients (in particular, the CR or PR rates to these treatments) is not 
known. Nevertheless, long-term survival was exceptional (<=5%) in all subgroups of 
patients who did not achieve CR after first-line treatment. Overall, the patients in CR have a 
relative chance of achieving long-term survival which is 5.0-fold higher than patients in PR, 
10-fold higher than patients in SD and 55-fold higher than patients in PD. Regarding long-
term survival, three subgroups of patients may therefore be distinguished according to 
response to first-line chemotherapy: 1) patients in CR, 2) patients in PR or SD, who were 
found to have a comparable outcome in terms of 5-year survival, and 3) finally patients in 
PD. In view of these results, a major goal of the treatment of patients with ASTS could be to 
improve the complete response rate to chemotherapy or to combined strategies with 
chemotherapy and surgery. However, complete response rates are low in ASTS, ranging 
from 0 to 10% with single agent or combination regimens in large series [1, 2, 3, 4, 5, 6, 7, 
8, 9, 10 and 11]. Another relevant parameter could be the rate of "non-progressive" 
disease, combining stable disease, partial and complete responses: not surprisingly, these 
three subgroups include almost all long-term survivors in the present series. Despite a large 
number of phase II trials, recent agents have shown a limited efficacy on ASTS [22, 23, 24 
and 25]. Therefore, strategies combining chemotherapy with surgery on multiple tumour 
sites to improve the rate of long-term survivors deserve to be evaluated to increase CR 
rate.  
However, the long-term survival of patients who achieve CR remains unsatisfactory since 
80% of these patients will relapse and die of their disease afterwards. Strategies to reduce 
the relapse rates in these potentially curable patients are therefore needed. High-dose 
chemotherapy has been proposed with this aim in mind in selected patients: five year 
survival rates over 50% were reported in some of these small uncontrolled studies [15, 16, 
17, 18, 19, 20 and 21]. Whether this only reflects a selection of patients still requires to be 
tested in a prospective randomised trial.  
In conclusion, these results indicate that a significant proportion of patients with ASTS can 
achieve long-term survival and probably cure after first-line chemotherapy with 
anthracyclines. Long-term survivors are observed in all subgroups of patients, even in those 
with a well established unfavourable prognosis, such as liver metastasis, and high grade 
tumours. The achievement of CR is the major parameter correlated to long-term survival 
and future clinical trials should include complete response as a major endpoint in the 
evaluation of therapeutic strategies. 
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Abstract 
The present study was set up just after the publication of the response evaluation criteria in 
solid tumors (RECIST) as a prospective validation exercise in soft tissue sarcoma. Forty-
nine patients were entered into a phase II clinical trial aiming at determining the activity and 
safety of ET-743 (Ecteinascidin) in second line advanced soft tissue sarcoma. Response to 
treatment and progression were monitored following the WHO criteria and RECIST. 
Discordances between WHO and RECIST criteria for the best response were reported for 
two cases: one no-change (WHO) reported as partial response (RECIST) and one 
progression (WHO) reported as no-change (RECIST). In terms of date of progression, 3 
patients progressed on WHO criteria while they were still stable with RECIST. Overall the 
results of the study would not have changed if RECIST had been used instead of WHO 
criteria.  
In conclusion, response criteria as defined by RECIST are adequate to measure response 
and progression in non-GIST soft tissue sarcoma and can be used instead of the modified 
WHO criteria.  
Introduction 
Response evaluation criteria in solid tumors (RECIST) was introduced in February 2000 to 
facilitate and improve the evaluation and the reporting of responses in early clinical trials 
aiming at determining the level of anti-tumor activity of new anti-cancer agents [1]. The new 
criteria gave much more precision as to how tumor lesions should be assessed and how 
responses should be reported, also taking into account modern imaging techniques. 
RECIST uses a uni-dimensional measure (the longest diameter) to quantify measurable 
tumor lesions as opposed to the bi-dimensional method (cross-sectional longest diameters) 
usually employed with most other sets of response criteria [2], [3] and [4]. On the basis of 
previous studies [3] and [5], RECIST defines measurable lesions as lesions with a minimum 
size depending on the method of investigation. Following a principle already implemented in 
the SWOG response criteria [3], the rules defining objective progression were voluntarily 
scaled down as compared to the WHO criteria so that the increase in measurable overall 
tumor burden should be greater with RECIST (20% in one dimension is equivalent to 44% 
in 2 dimensions) than with WHO criteria (25% in 2 dimensions) to qualify for progression. 
Following this last criterion, there was some concern that time to progression could be 
longer using RECIST as opposed to WHO criteria and this was identified up front as an 
issue requiring some attention in future trials before drawing definitive conclusions.  
The objective measurement of tumor lesions has been used for decades in advanced soft 
tissue sarcoma to screen new agents or new regimens. The original WHO criteria have 
been adapted (modified WHO criteria) to improve the accuracy of response assessment in 
this tumor type [5] and [6]. The aim of the current study was to test RECIST in a prospective 
trial in parallel with WHO criteria and establish new references (using RECIST) in this tumor 
type for future trials if significant differences were identified compared with modified WHO 
criteria.  
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Patients and methods 
The present study was conducted in the framework of a non-randomised phase II study 
investigating the anticancer activity and safety of Ecteinascidin (ET-743 – a novel 
tetrahydroisoquinoline compound isolated from the marine ascidian Ecteinascidia turbinata) 
in pre-treated advanced soft tissue sarcoma. The clinical trial was conducted by the EORTC 
Soft Tissue and Bone Sarcoma Group (STBSG). After the publication of the RECIST in 
February 2000, the original clinical trial protocol was officially amended to extend the 
sample size and collect information prospectively and in parallel about response and 
progression as assessed both by RECIST and WHO criteria. Patients eligible for entry in 
the study were required to have histologically proven measurable metastatic or 
unresectable loco-regional recurrent soft-tissue sarcoma. Mesothelioma, chondrosarcoma, 
neuroblastoma, osteosarcoma, Ewing’s sarcoma, embryonal rhabdomyosarcoma and 
dermatofibrosarcoma were excluded. Patients with gastro intestinal stromal tumors (GIST) 
were treated in a separate study.  
All patients were to have a documented progressive disease at inclusion, with defined 
target lesions at physical examination, on X-rays and CT scan. For the purpose of this 
project, the eligibility criteria required the presence of at least one measurable lesion 
fulfilling the definition of both (modified) WHO criteria and RECIST. The protocol specified 
that maximum three target lesions per organ and maximum five target lesions overall were 
to be reported and used for assessing response. WHO criteria were used as reference 
criteria for therapeutic decisions (discontinuation of treatment).  
Other eligibility criteria were standard and have been outlined in detail in a previous paper 
together with the results of the therapeutic activity of ET-743 [7].  
ET-743 was administered at a dose of 1.5 mg/m2 intravenously as a 24 h continuous 
infusion every 3 weeks using a central venous line.  
Response to treatment was evaluated every 2 cycles (every 6 weeks), with repeated clinical 
and relevant radiological assessments based on disease extension at presentation. For all 
responding patients, the hospital records and all available films were reviewed by two 
independent investigators. A response was accepted only if they reached consensus. In the 
absence of consensus the worst response category was assigned. Patients were 
considered evaluable for response if they had received a minimum of two cycles of 
treatment. In case of rapidly progressive disease after one course, the patient was removed 
from study and classified as treatment failure. If response had not been assessed, patients 
were included in the following categories: early death from toxicity in case of death 
occurring within 6 weeks due to signs of toxicity; early death from malignant disease if 
death occurred within 6 weeks after commencing chemotherapy due to soft tissue sarcoma 
and without signs of toxicity; a further classification was early death from other cause if 
death occurred in the same period of a cause not related to malignant disease. Patients 
who had stable disease or exhibited complete or partial responses remained on treatment 
until treatment completion (6 cycles), disease progression, unacceptable toxicity or patient 
refusal. Patients with evidence of drug related clinical benefit were allowed to continue on 
therapy after 6 cycles.  
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The Simon two stage design has been separately applied to each patient cohort (one 
cohort before and one cohort after the amendment) to allow determination of response 
rates and progression with RECIST. All analyses presented in this paper are exploratory 
and descriptive and have been produced using VISTA, the software developed by EORTC 
to handle clinical trial data.  
Results 
Between March 2000 and November 2000, 49 patients were recruited by 7 participating 
centers. Two patients were initially declared ineligible by the study coordinator for the main 
efficacy analysis. One patient had a lung target lesion with a longest diameter of 17 mm on 
CT scan while the selection criteria required at least one target lesion >20 mm and another 
patient had only one target lesion that had been previously irradiated. However, considering 
an intent to treat analysis for all patients for whom we had data on both WHO and RECIST 
evaluations, these patients have been included in the present analysis. The original 
localisation of the disease is described in Table 1.  
Table IV-1: Primary sites of disease  
 n = 49 (%) 
Head and neck 2 (4) 
Trunk 7 (14.3) 
Visceral intra-abdominal 5 (10.2) 
Retroperitoneum 6 (12.2) 
Uterus 8 (16.3) 
Girdle 5 (10.2) 
Lower arm 16 (32.6) 
 
Most of the patients had either one (21 patients/42.9%) or two (14 patients/28.6%) different 
anatomic sites involved (considering target and non-target lesions) and only 10 (20.4%) and 
4 (8.2%) patients had 3 or 4 different sites involved, respectively. Twenty-nine patients had 
only one target lesion and 11 patients had 2 target lesions (Table 2). Target lesions were 
located in one organ only for 44 patients (Table 3) and the distribution of lesions per 
organ/system is described in Table 4. Following the modified WHO criteria used for decision 
making in this protocol 2 patients presented a partial remission (PR), 30 patients achieved 
no-change (NC) and in 17 patients progressive disease was recorded as best overall 
response. The comparison of response assessment between WHO criteria and RECIST is 
described in Table 5. Discordances between WHO criteria and RECIST for the best 
response were reported for two cases: one no change (NC) (WHO) reported as partial 
response (PR) (RECIST) and one progressive disease (PD) (WHO) reported as NC 
(RECIST).  
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Table IV-2: Number of target lesions per patient 
WHO RECIST 
 1 2 3 4 5 Total 
1 29 (100%)     29 (59.2%) 
2  11 (100%)    11 (22.4%) 
3   7 (100%)   7 (14.3%) 
4    1 (100%)  1 (2%) 
5     1 (100%) 1 (2%) 
Total 29 11 7 1 1 49 
Table IV-3: Number of target lesions by organ per patient 
Lesions Organs 
 1 2 3 Total 
1 29 (65.9%)   29 (59.2%) 
2 7 (15.9%) 4 (100%)  11 (22.4%) 
3 7 (15.9%)   7 (14.3%) 
4   1 (100%) 1 (2%) 
5 1 (2.3%)   1 (2%) 
Total 44 4 1 49 
Table IV-4: Organ/system involved (patients may have more than 1 site involved) 
Involved sites Any lesions (n = 49)  Target lesions (n = 49)  
Primary 18 11 
Lymph nodes 6 3 
Lung 33 22 
Liver 9 6 
Skin 1 – 
Other soft tissue sites 16 15 
Bone 6 – 
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Table IV-5: Best response to therapy WHO vs. RECIST  
WHO RECIST 
 PR NC PD Total 
PR 2   2 (4.1%) 
NC 1 29  30 (61.2%) 
PD  1 16 17 (34.7%) 
Total 3 (6.1%) 30 (61.2%) 16 (32.6%) 49 
PR, partial response; NC, no change; PD, progressive disease. 
 
The progression status evaluated according to WHO criteria or RECIST is presented in 
Table 6. In this analysis, 15 patients were not evaluable for the comparison RECIST/WHO. 
Two patients stopped treatment for toxicity reasons before progression and 13 patients 
progressed after the end of the planned treatment period and had no comparative 
measurements recorded at the time of progression. Among the remaining 34 patients, 3 
patients were identified as PD following the WHO criteria while they were still stable (NC) 
following RECIST. For 2 of these patients, therapy was discontinued (as per protocol) at the 
time of WHO progression. One patient died rapidly and the other patient survived another 
year. The third patient was continued on therapy for another 6 months despite WHO 
progression (erroneously reported as NC (WHO) by the investigator but truly NC following 
RECIST) achieving a partial remission (WHO and RECIST) that remained stable for another 
year. In the present study, the decision rules set up for the further development of ET-743 
would not have been affected if RECIST had been used instead of the modified WHO 
criteria.  
Table IV-6: Timing of progression with RECIST and WHO criteria  
 Progression, n = 49 (%) 
Non-evaluable 15 (30.6) 
  
Same date of progression 31 (63.3) 
Progression with new lesion(s) 18 (58) 
Progression by increase of pre-existing of tumor burden 13 (42) 
  
Progression by RECIST after progression by WHO 3 (6.1) 
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Discussion 
The present study is interesting for several reasons including that this is the first study 
prospectively testing both RECIST and WHO criteria in advanced soft tissue sarcoma. 
Using the response rate to decide whether or not to continue or stop further investigations 
with ET-743 the same decision would have been taken whether WHO criteria or RECIST 
had been used. These decision rules were built into the protocol. However based upon the 
observed specific character of the anti-tumor activity generated by ET-743 (long lasting 
absence of progression), in further planning more attention was given to the time to 
progression and progression rate (or rate of progression arrest) to quantify the activity of 
ET-743. As WHO criteria were initially designated as the criteria on which the therapeutic 
decisions should be taken, it has not been possible to assess and compare progression 
rates obtained with the two sets of response criteria especially for long lasting disease 
stabilisation after treatment completion. Should RECIST have been selected as the 
principal criteria for this study a long and difficult debate would have followed whether the 
very long time to progression was only due to the use of RECIST instead of WHO criteria, 
or due to the intrinsic anti-tumor activity of ET-743. This constitutes clearly one of the 
limitations of this study as is the case for all prospective validation studies published so far 
[8], [9], [10], [11], [12], [13], [14] and [15]. This study, albeit relatively small, suggests that for 
screening types of trials such as the phase II study design, the simpler RECIST is as 
satisfactory as the more complex WHO criteria, particularly for development planning. This 
study does not enable us to assess whether if RECIST was used as principal selection 
criteria for response, if it would have cut down the number of eligible patients compared to 
WHO criteria (with no minimum size for tumor lesion) since the WHO modified criteria used 
in this study (and previous studies in the same tumor type) are even more strict in the 
selection of patients than RECIST.  
It is also important to note that, as in many other tumor types, progression is identified with 
the appearance of a new lesion in a majority of patients (58% in this study) as opposed to 
an objective increase in existing tumor burden. This confirms that although a relative 
precision is needed to measure the overall tumor burden, the true impact of measurement 
errors as well as the importance given to the magnitude of tumor burden increase (25% in 2 
dimensions with WHO or 20% in one dimension with RECIST) on the correct estimation of 
the progression rate is relatively small. In the present study, only three patients (6.1%) were 
identified as progressing according to the modified WHO criteria while they were still 
considered as stable using RECIST. The natural history of these three patients (after being 
identified as progressing following the WHO criteria) supports the concept on which the 
progression rule in RECIST has been elaborated. That is to say that prolonging the time to 
progression by requiring a larger increase in tumor burden than with former WHO criteria 
may have almost no impact on patients truly progressing (the delay between WHO and 
RECIST progression will be very small). However, it may on the other hand help patients 
who might still benefit from further treatment and who are therefore less exposed to 
unfortunate therapeutic decisions based on measurement imprecision or errors.  
Even though up to five target lesions could be reported as per protocol the large majority of 
patients had less than 3 target lesions reported and almost all of them were situated in the 
same organ/system. It is, however, difficult to interpret these data without knowing the real 
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number of potential target lesions at baseline. One could indeed be victim of under-
reporting of target lesions or on the contrary conclude that the problem of having to follow a 
lot of target lesions (up to five following this protocol) is not a true problem in this tumor 
type.  
Of the eight currently published prospective validation studies comparing WHO criteria to 
RECIST, four involve primary lung cancer [8], [11], [13] and [14], one involves metastatic 
colorectal cancer [9], and one lung and liver lesions from breast cancer [10], and finally two 
involve mesothelioma [12] and [15]. Apart from the mesothelioma studies all indicate a 
similar outcome in terms of response rates regardless whether RECIST or WHO criteria are 
used. Because of the particular characteristics of mesothelioma, it can be expected that 
both RECIST and WHO are not adequate to measure the true tumor burden. Several 
solutions have been proposed but there is currently no consensus on a preferred system. 
Three of the studies performed provide information on WHO criteria and RECIST in terms 
of progression [9], [10] and [13] but as indicated and importantly, none of these studies 
used RECIST as primary criteria and, therefore, the overall conclusion drawn from 
comparing RECIST and WHO criteria remains slightly biased. In two studies [9] and [10], as 
in the current one, few patients with PD using WHO criteria would still have been 
considered as stable with RECIST. In one (small) study [13], there was no difference in time 
to progression when using either RECIST or WHO criteria. Apart from mesothelioma, all 
other studies performed confirmed that RECIST (and the uni-dimensional approach) is 
suitable to measure response and progression. In conclusion, our study confirms that 
RECIST can be used for decision making in screening studies in soft tissue sarcomas. 
Putting this study in perspective with other studies in more common tumor types supports 
the implementation of RECIST as standard criteria for response evaluation but also for 
monitoring progression.  
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Abstract 
We have estimated progression-free rates (PFR) for various groups of soft-tissue sarcoma 
patients from our clinical trials database, to provide reference values for conducting phase II 
studies with PFR as the principal end-point. In 146 pretreated patients receiving an active 
agent, the PFR estimates were 39 and 14% at 3 and 6 months; with inactive regimens (234 
patients), those estimates were 21 and 8% respectively. In 1154-non-pretreated patients, 
PFR estimates varied from 77% (synovial sarcoma) to 57% (malignant fibrous histiocytoma 
(MFH)) at 3 months, and from 56% (synovial sarcoma) to 38% (MFH) at 6 months. In 61 
leiomyosarcomas from gastrointestinal origin, the corresponding figures were 44 and 30%, 
respectively. Consequently, for first-line therapy, a 6-month PFR of >=30–56% (depending 
on histology) can be considered as a reference value to suggest drug activity; for second-
line therapy, a 3-month PFR of >=40% would suggest a drug activity, and <=20% would 
suggest inactivity.  
Introduction 
Response to therapy, based on a measured decrease in the size of cancer lesions, is 
considered to be the most effective end-point to document biological anticancer activity of 
cytoreductive agents and consequently to identify potential new cytoreductive drugs. The 
response evaluation criteria in solid tumours (RECIST) criteria [1] provide a harmonised 
method of response evaluation. For non-cytoreductive anticancer agents, biological activity 
is frequently not expected to translate into shrinkage of lesions, but rather in stabilisation of 
disease. The RECIST guidelines recognise that progression-free survival and/or time to 
progression may be a valuable alternative end-point to provide an initial estimate of the 
biological effect for these agents.  
The classical phase II designs [2, 3 and 4] are applicable to any situation where the activity 
of the new agent is characterised by a binary variable that objectively defines ‘success’ 
versus ‘failure’ for each patient. Our proposal is to consider absence of progression (or the 
progression-free rate (PFR)) at a fixed time point as a primary end-point of phase II trials 
with non-cytotoxic drugs. This is one of the different approaches proposed by Korn [5] for 
phase II clinical trials with cytostatic agents.  
In the above-mentioned designs, the sample size and decision rules are computed on the 
basis of the ‘success’ rates expected after treatment with an active therapeutic agent (P1), 
as well as treatment with an inactive agent (P0). These reference rates will obviously differ 
if the definition of ‘success’ is changed from objective response to progression-free status.  
In soft-tissue sarcomas, only three cytotoxic drugs (doxorubicin, ifosfamide and 
dacarbazine) have, so far, demonstrated activity. New non-cytotoxic agents, often targeting 
specific histological subtypes, are now being explored. In addition, given the low objective 
response rate observed with the above three agents, for new cytotoxic agents information 
on PFRs will be relevant. The aim of this study was to provide appropriate baseline 
references for conducting phase II trials with PFRs as end-points in this disease.  
In this study, we have explored the Soft Tissue and Bone Sarcoma Group (STBSG) 
database to estimate the PFRs that can be reasonably expected from an active agent or 
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combination, and from an inactive agent in soft-tissue sarcoma. This will guide the choice of 
the ‘P0’ and ‘P1’ parameters of phase II statistical designs.  
Patients and methods 
The European Organization for Research and Treatment of Cancer (EORTC) STBSG has 
investigated in prospective clinical trials different new agents and combination therapies for 
soft-tissue sarcoma, both in pretreated and non-pretreated patients [6, 7, 8, 9, 10, 11, 12, 
13, 14, 15, 16 and 17].  
Pretreated patients included in this analysis had been included in 12 clinical trials and 
treated with 11 different agents, according to the 13 therapeutic regimens detailed in 
Table 1 (one regimen per trial, except for a randomised trial with regimens B and C).  
Table V-1: Therapeutic regimen 
Regimen Treatment description 
A Dacarbazine 1.2 g/m2, 20 min infusion, q 3 wks 
B Ifosfamide 5 g/m2, 1 day infusion, q 3 wks 
C Ifosfamide 3 g/m2.day, 4 hours infusion, days 1,2,3, q 3 wks 
D Ifosfamide 12 g/m2, 3 days infusion, q 4 wks 
E Mitozolomide 90 g/m2, 1 hour infusion, q 6 wks 
K Etoposide, 50 mg/m2.day, p.o., d1-21, q 4 wks 
q, every; wks, weeks; i.v., intravenous; p.o., orally;  
L-MTP/PE, liposomal muramyl tripeptide phophatidylethanolamide  
 
All of the studies required histological evidence of soft-tissue sarcoma of one of the 
following cell types: malignant fibrous histiocytoma (MFH), liposarcoma, 
rhabdomyosarcoma, synovial sarcoma, malignant paraganglioma, fibrosarcoma, 
leiomyosarcoma, angiosarcoma including haemangiopericytoma, neurogenic sarcoma, 
unclassified sarcoma, and miscellaneous sarcoma including mixed mesodermal tumours of 
the uterus. Malignant mesothelioma, chrondrosarcoma, neuroblastoma, osteosarcoma, 
Ewing's sarcoma and embryonal rhabdomyosarcoma were excluded. Other criteria included 
the presence of at least one bidimensionally measurable lesion (according to the World 
Health Organization (WHO) criteria), evidence of progression within 4 or 6 weeks prior to 
treatment, absence of symptomatic Central Nervous System (CNS) metastases, and 
informed consent. Eligibility in terms of age and performance status, as well as upper and 
lower limits of haematological and biological parameters varied slightly amongst the trials, 
as shown in Table 2. Extent of allowed prior chemotherapy varied largely between 
protocols. Although not formally required in all trials, most patients were pretreated with at 
least one chemotherapy regimen. Non-pretreated patients were excluded from the present 
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analysis, as well as patients that were not eligible for the trial, and patients who did not 
receive any protocol treatment.  
Table V-2: Selected patient populations 
Trial regimen A B-C D E F G H I J K L M 
Evidence of 
progression  
   within 
 
4 
wks 
 
6 
wks 
 
6 
wks 
 
4 
wks 
 
4 
wks 
 
2 
mon 
 
4 
wks 
 
6 
wks 
 
6 
wks 
 
6 
wks 
 
6 
wks 
 
6 
wks 
Age (years) 15-
75 
15-
75 
15-
65 
15-
75 
15-
75 
18-
75 
15-
75 
15-
75 
17-
75 
15-
75 
15-
75 
15-
75 
PS 0-1 0-1 0-1 0-1 0-2 0-2 0-2 0-2 0-1 0-1 0-1 0-1 
Prior chemo. 
Regimen 
-- 1  -- -- 0-1 0-1      
     single agent   0-2     0-2 0-2 0-2 2 2 
     OR multidrug   0-1     0-1 0-1 0-1 1 1 
Prior drugs 
≤ 
3** 
1* -- ≤ 4 ≤ 4 -- -- -- -- -- -- --00 
WBC (10**9/l) ≥ 3 ≥ 4 ≥ 4 > 4 > 4 > 4 ≥ 4 ≥ 4 > 
3.5 
≥ 
3.5 
≥ 4 ≥ 4 
PLA (10**9/l) ≥ 
100 
≥ 
100 
≥ 
100 
> 
125 
> 
125 
> 
150 
≥ 
100 
≥ 
100 
> 
100 
≥ 
100 
≥ 
100 
≥ 
100 
Hemoglobin (g/dl) -- -- -- -- -- > 11       
Creatinine 
(micromol/l) 
≤ 
150 
≤ 
150 
 
≤ 
150 
≤ 
150 
 
≤ 
150 
≤ 
150 
≤ 
150 
≤ 
150 
≤ 
120 
≤ 
120 
Creatinine (mg/dl) -- --  -- -- ≤ 
1.5 
      
Creatinine 
clearance (ml/min) -- -- ≥ 70 -- -- ≥ 60 -- -- > 60 -- 
Or > 
65 
Or > 
65 
Bilirubine 
(micromol/l) ≤ 25 ≤ 25 ≤ 30 ≤ 25 ≤ 25  ≤ 20 ≤ 25 ≤ 25 ≤ 20 ≤ 30 ≤ 30 
Bilirubine (mg/dl) -- --  -- -- ≤ 
1.5 
      
Albumine (g/l) -- ≤ 25 ≤ 25 -- --  ≤ 25 -- -- ≤ 30 ≤25 ≤ 25 
Transaminases  
(* UNL) -- --  -- -- 
≤ 
1.25 
-- -- < 2 -- -- -- 
Alkaline phosph. 
(*UNL) -- --  -- -- 
≤ 
1.25 
      
Prior nephrectomy -- -- No -- -- -- -- -- -- -- -- -- 
wks, weeks; PS, Performance Status; chemo, chemotherapy; WBC, white blood cells; PLA, platelets; 
UNL, upper normal limit. 
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The 1154 non-pretreated cases included in this analysis were selected from the previously 
reported cohort of more than 2000 cases [18]. Therapeutic regimens have been previously 
described. Patients selected for this analysis had an externally confirmed diagnosis of the 
six most frequent histological subtypes.  
Response to therapy was evaluated according to the WHO criteria in all trials. Complete 
and partial responses were reviewed by at least two investigators of the group. This review 
process was recently validated by an external radiologist [19]. Patients were followed for 
progression every 6 weeks. In most studies, patients were also followed for survival after 
progression.  
Data have been collected in a consistent way for all of these trials, and we have selected 
from the resulting database the following groups of patients:  
• Patients treated with an active drug (ifosfamide or dacarbazine) after failure of an 
anthracycline-containing regimen (146 cases); PFRs observed in this group 
provide reference values for the parameter P1 in pretreated patients. 
• Patients that, after failure to prior chemotherapy, were treated within nine studies 
on investigational agents that unfortunately did not demonstrate substantial 
antitumour activity at the tested dose and schedule (234 cases): PFRs observed in 
this group provide reference values for the parameter P0 in pretreated patients. 
• Patients treated with a first-line active drug or combination (anthracycline-
containing regimen), with an externally confirmed diagnosis of leiomyosarcoma 
(531 cases), MFH (217 cases), synovial sarcoma (115 cases), liposarcoma (110 
cases), fibrosarcoma (68 cases) and neurogenic sarcoma (113 cases): these 
groups provide reference values for the parameter P1 in non-pretreated patients, 
for the six most frequent histological subgroups. 
Understandably, we do not have any data on patients treated with first-line inactive agents 
or combinations, and we are therefore unable to provide reference values for the parameter 
P0.  
In view of the large number of histological subtypes of soft tissue sarcomas, the database of 
pretreated cases was not large enough to allow us to provide separate estimates for the 
different tumour types.  
In all groups of patients, the 3-month and 6-month PFRs have been evaluated by the 
Kaplan–Meier method [20]. Standard errors were estimated by the Greenwood formula [21]. 
For pretreated patients, the prognostic value of baseline characteristics was estimated in 
univariate (logrank test [22]) and multivariate (Cox regression [23]) analyses.  
The following factors were explored (when available): age, performance status at the start 
of therapy, type of prior therapy, number of prior therapeutic regimens and agents, 
presence of liver metastases and time elapsed since the initial diagnosis of sarcoma.  
For non-pretreated patients, we have previously published a detailed prognostic factor 
analysis on the complete database [18].  
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Results 
Pretreated patients 
From the 11 investigated agents, only two demonstrated significant antitumour activity, in 
terms of objective responses: ifosfamide and dacarbazine; these were considered as ‘active 
drugs’ in our analysis. For the nine other agents, no or few responses were observed at the 
investigated dose and schedule, and we therefore considered these as ‘inactive regimens’.  
A total of 380 patients were included in this analysis, 146 of them treated with active drugs 
(ifosfamide or dacarbazine) and 234 treated with inactive regimens. Patient characteristics 
are summarised in Table 3. 
Table V-3: Patients characteristics 
Trial  A B/C D E F G H I J K L M 
# cases  45 76 25 26 33 28 21 19 28 26 22 31 
Sex Males 56 47 56 46 42 61 57 47 46 50 68 48 
0 36 33 32 35 18 21 43 21 32 28 45 32 Performance 
status 2+ 16 5 0 0 21 25 14 16 4 0 0 0 
< 40 yrs 42 20 28 28 15 36 38 42 25 35 14 16 
Age 
> 60 yrs 24 22 20 28 30 14 19 16 29 27 18 35 
< 6 mon -- 13 28 -- -- 4 14 11 0 4 14 0 Initial 
diagnosis > 24 mon -- 34 36 -- -- 46 48 32 52 38 18 52 
Liver Involved 7 21 36 19 30 29 29 32 25 12 18 26  
Leiomyo. 30 45 24 23 39 29 24 32 21 31 32 35 
MFH 18 11 8 12 9 18 19 16 11 12 5 0 
Synovial 18 7 12 19 12 21 10 11 11 12 5 23 
Neurogen. 7 7 0 8 3 14 19 11 11 4 5 6 
Liposarc. 2 13 4 8 6 4 10 5 11 12 14 10 
Histology 
Fibrosarc. 2 1 0 4 9 0 14 0 4 0 5 0 
Adjuv.only 9 24 24 4 12 7 14 16 7 27 23 13 
> 1 regim. -- 0 1 -- -- 4 0 11 32 12 32 32 
1 drug 17 100 36 -- 0 25 38 58 39 8 36 42 
Prior 
chemo- 
therapy 
2 drugs 67 0 32 -- 18 64 48 37 54 77 41 48 
mon, months; yrs, years; Leiomyo, leiomyosarcoma; MFH, malignant fibrous histiocytoma;  
Neurogen., neurogenic sarcoma; Liposarc., liposarcoma; Fibrosarc., fibrosarcoma 
The Kaplan–Meier estimate of the PFR is shown in Fig. 1 for the whole cohort of patients 
and in Fig. 2 for the two groups of patients separately. The 3-month and 6-month PFRs 
were 39 and 14%, respectively, for patients treated with an active drug, and 21 and 8%, 
respectively, for patients treated with an inactive regimen. For the whole cohort, the rates 
were 28 and 10%, respectively. Detailed results are shown in Table 4.  
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Figure V-1: 
Progression-free rate 
for the whole cohort of 
pretreated patients. 
Kaplan-Meier estimate; 
O, observed events;  
N, number of patients 
 
 
 
Figure V-2: 
Progression-free rate 
for patients pretreated 
with an inactive or with 
an active agent. 
Kaplan-Meier estimate; 
O, observed events;  
N, number of patients 
 
 
Table V-4: Progression free rates (PFRs) in pretreated patients 
Type of drug # cases 3 months PF rate 6 months PF rate 
  Estimates Std error Estimates Std error 
Inactive 234 21 % 3 % 8 % 2 % 
Active 146 39 % 4 % 14 % 3 % 
All patients 380 28 % 3 % 10 % 2 % 
(months)0 3 6 9 12
0
20
40
60
80
100
O N Number of patients at risk :
357 380 102 34 19 12
 
(months) 0 3 6 9 12 
0 
20 
40 
60 
80 
100 
O N Number of patients at risk : 
221 234 47 16 5 1 
136 146 55 18 14 11 
Inactive 
Active 
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Only three prognostic factors emerged from the univariate analysis, and they all remained 
significant (or of borderline significance) in the multivariate Cox model:  
• Treatment with an active drug (P<0.0001) 
• Interval since the initial diagnosis of disease (P=0.014) and 
• Performance status (P=0.08). 
Non-pretreated patients 
In this group of patients, the 3-month PFRs varied from 77% (synovial sarcoma) to 57% 
(MFH) and the 6-month PFRs from 56% (synovial sarcoma) to 38% (MFH), the standard 
error (S.E.) was <5% in all estimates except for fibrosarcoma (6%).  
Most of the trials were conducted before the identification of gastrointestinal stromal tumour 
(GIST) as a separate entity, and these cases were consequently classified as 
‘leiomyosarcoma’ in our database. However, a gastrointestinal origin of disease was 
documented in 61 leiomyosarcomas, and we assumed that most of those cases would 
today be classified as GIST. In this sub-group, 3-month and 6-month PFRs were 44 and 
30%, respectively (S.E.=6%). Detailed results are shown in Table 5.  
The prognostic factors of response and survival were the same as those already reported 
for the whole cohort [18].  
Table V-5: Progression-free rates (PFRs) in non pretreated patients 
Histology # cases 3 months PF rate 6 months PF rate 
  Estimates Std error Estimates Std error 
Leiomyosarcoma (all) 531 58 % 2 % 40 % 2 % 
MFH 217 57 % 3 % 38 % 3 % 
Synovial sarcoma 115 77 % 4 % 56 % 5 % 
Neurogenic sarcoma 113 67 % 5 % 45 % 5 % 
Liposarcoma 110 64 % 5 % 55 % 5 % 
Fibrosarcoma 68 62 % 6 % 45 % 6 % 
Leiomyosarcoma  
from GI origin 
61 44 % 6 % 30 % 6 % 
PF rate, progression free rate ; MFH, malignant fibrous histiocytoma; GI, gastrointestinal.  
Progression free rate as the principal end point 
61 
Discussion 
Relevance of the results 
Our proposal is to use PFRs retrospectively estimated from our database as reference 
values for the P0 and P1 parameters in the statistical design of future phase II trials. These 
estimates are, however, provided with a standard error around 5%.  
Phase II trials are screening studies, designed to decide if a new agent is worth further 
investigation in an appropriate phase III programme. The decision is based on observations 
assumed to reflect biological antitumour activity, but not necessarily a therapeutic benefit. If 
results of the phase II trial are consistent with the level of activity expected from an active 
drug, the new agent deserves further testing. If results of the phase II trial are consistent 
with the level of activity expected from an inactive drug, the new agent is rejected from 
further testing. The sample size is computed to ensure that these two decision rules are 
mutually exclusive. It should be underlined that a phase II trial is considered as positive 
when the drug activity is consistent with the one of an active agent with a confidence level 
(β) as low as 5 or 10%.  
Therefore, we feel that parameters estimated from clinical trial data with an error rate of 5% 
may be used as a guide to proceed with the clinical development programme of a new 
agent, but not to prove the therapeutic value of the drug. However, even with a drug like 
dacarbazine, by many still considered as an active drug in this group of diseases, the 
responses observed were not durable leading to a shorter progression-free time than 
observed with some investigational agents. In addition, recent results using some new 
cytotoxic agents suggest that response is not the best end-point for phase II studies on 
which to base important drug development decisions.  
Selection of the appropriate time point for evaluation 
The selection of an appropriate time point for PFR evaluation is a compromise between the 
need to avoid false-positive trials, and practical complications linked to a long period of 
observation. If the disease is slowly progressing, absence of documented progression at 
the first disease evaluation (generally 6–8 weeks after the start of treatment) may not reflect 
any drug activity, but only the natural course of the disease. Our data showed little 
discrimination between active and inactive regimens at this time point. However, it is 
expected that all patients should be evaluable, and, therefore, would be treated until the 
evaluation point in the absence of progression. A study requiring a long treatment and 
follow-up period would be difficult to conduct. Therefore, we propose to evaluate the 
progression status 3 and 6 months after the start of treatment.  
Despite a close study monitoring, it may be difficult to avoid losing a few patients to follow-
up before documented progression. These patients will therefore not be fully evaluable for 
the primary end-point, and the sample size should be accordingly increased. However, 
instead of excluding these patients from the analysis, the success rate can be estimated by 
an actuarial method (preferably Kaplan–Meier), and these patients would be censored at 
the date of the last follow-up. The Greenwood formula can be used to estimate the standard 
error. Green [24] has proposed methods to adapt the decision rules of several phase II 
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designs when the attained sample size is not the one that was initially planned. These 
methods can be extended to actuarial estimates of success rates.  
Assessment of progression-free status 
The primary end-point of a clinical trial needs to be objectively assessable. The RECIST 
criteria provide a method for progression evaluation. According to these guidelines, several 
events are considered as evidence of progression: appearance of new lesions, increase of 
at least 20% in the sum of the diameters of the target lesions, and unequivocal increase in 
the size of non-measurable disease. This last criterion needs to be confirmed by an external 
review. Therefore, in trials using these types of end-points, an external review may still be 
needed. It should also be underlined that measurable disease at trial entry is still required.  
Stable disease cannot be considered as evidence of the treatment activity if the disease 
was not progressing before the start of treatment. Therefore, only patients with documented 
progressive disease should be selected for these trials. This requires at least two sets of 
objective tumour measurements before inclusion, which would restrict the eligible 
population.  
Selection of the statistical design 
The most popular statistical designs for phase II trials are the two steps optimal and 
minimax designs proposed by Simon [2]. The ‘success rate’ must be evaluated on a first 
patient cohort before the decision to proceed to the full size study, which requires the 
interruption of the trial until the first cohort has reached the evaluation time point. This is 
also true for the Bryant and Day two-step design [25] that also controls for toxicity. The 
complexity will be increased further for designs that have three or more steps, such as 
those proposed by Ensign [26] and Fleming [3].  
Fleming [3] has also proposed a single step design based on a similar hypothesis. This 
simplifies the conduct of the trial because it does not need to be interrupted, but the 
absence of an early stopping rule may be unethical in early phase II trials, when the 
investigational agent has not yet demonstrated any activity.  
The design proposed by Gehan [4] is sometimes used in early phase II trials, when a 
decision rule is not crucial. This method tests the compatibility of the observed success rate 
with the rate of an active agent, but does not formally reject agents with a positive, but low, 
success rate. As our data show that a small proportion of patients remain disease-free at 3 
or 6 months, even when treated with an inactive regimen, this design is not appropriate 
when activity is characterised by the absence of progression.  
Other end-points 
Other end-points are currently used for phase II trials on non-cytotoxic drugs, or in situation 
where objective responses are not expected.  
One of them is the ‘clinical response benefit’ where success is defined as the occurrence of 
either an objective response (according to RECIST criteria), or the absence of progression 
at a predefined time point (fixed between 3 and 6 months). The difference with our proposal 
is that patients who respond rapidly after the start of treatment, but progress before this 
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fixed time point are considered as successes. This design is probably more relevant to trials 
on rapidly progressing disease, when very few responses are expected, but disease 
stabilisation would be considered as a success. It is, however, difficult to provide objective 
reference of ‘success rates’ with this end-point from existing data. It will also be difficult to 
use censored progression data in the analysis.  
Mick and colleagues have proposed to use a ‘growth modulation index’, defined as the ratio 
between the time to progression observed with the new agent, and time to progression 
observed with the most recent prior anticancer treatment of the same patient [27].This 
method is theoretically very attractive, but only applicable to patients who have already 
failed a prior treatment, and for whom the time to previous progression was accurately 
documented. This restricts both the types of studies (on pretreated patients) and the eligible 
population (data availability).  
Conclusions 
To conclude, for phase II trials of non-cytotoxic agents in soft-tissue sarcoma, we propose 
to use standard phase II designs, with 3-month or 6-month PFRs as the principal end-
points. Reference values for the P0 and P1 parameters have been evaluated from the 
STBSG database for different groups of patients. Confirmation of these values from other 
databases would be useful. Time to progression is more difficult to evaluate than objective 
response, and its use as a principal end-point should be restricted to situations where a 
decrease of the tumour volume is not expected. Phase II trials conducted with this end-
point are still simple screening studies and are not intended to provide more information 
than a justification to further investigate a new treatment. Sufficiently powered phase III 
trials remain the only way to document the therapeutic benefit provided by a new agent.  
 
References 
1. P. Therasse, S.G. Arbuck, E.A. Eisenhauer et al., New guidelines to evaluate the 
response to treatment in solid tumors. J. Natl. Cancer Inst. 92 (2000), pp. 205–216. 
2. R. Simon. Optimal two-stage designs for phase II clinical trials. Controlled Clinical 
Trials 10 (1989), pp. 1–10. 
3. T.R. Fleming. One-sample multiple testing procedure for phase II clinical trials. 
Biometrics 38 (1982), pp. 143–151. 
4. E.A. Gehan. The determination of the number of patients required in a preliminary 
and a follow-up trial of a new chemotherapeutic agent. J. Chron. Dis. 13 (1961), pp. 
346–353. 
5. E.L. Korn, S.G. Arbuck, J.M. Pluda, R. Simon, R.S. Kaplan and M.C. Christian , 
Clinical designs for cytostatic agents: are new approaches needed?. J. Clin. Oncol. 
19 (2001), pp. 265–272. 
6. J.M. Buesa, H.T. Mouridsen, A.T. van Oosterom et al., High-dose DTIC in advanced 
soft tissue sarcomas in the adult. Ann. Oncol. 2 (1991), pp. 307–309. 
Chapter V 
64 
7. A.T. Van Oosterom, K. Krzemienlecki, O.S. Nielsen et al., Randomized phase II 
study of the EORTC Soft Tissue and Bone Sarcoma Group comparing two different 
ifosfamide regimens in chemotherapy untreated advanced soft tissue sarcoma 
patients. Proc. ASCO. J. Clin. Oncol. 16 (1997), p. 496a. 
8. O.S. Nielsen, I. Judson, Q. Van Hoesel et al., Effect of high-dose ifosfamide in 
advanced soft tissue sarcomas. A multicentre phase II study of the EORTC soft 
tissue and bone sarcoma group. Eur. J. Cancer 36 (2000), pp. 61–67. 
9. R. Somers, A. Santoro, J. Verweij et al., Phase II study of mitozolomide in advanced 
soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group. 
Eur. J. Cancer 28A (1992), pp. 855–857. 
10. D.J.T. Wagener, R. Somers, A. Santono et al.for The European Organization for 
Research, Treatment of Cancer Soft Tissues and Bone Sarcoma Group, Phase II 
study of nimustine in metastatic soft tissue sarcoma. Eur. J. Cancer 27 (1991), pp. 
1604–1605. 
11. P. Kerbrat, R. Somers, J. Verweij et al., Phase II study of fotemustine in advanced 
soft tissue sarcoma. A trial of the EORTC Soft Tissue and Bone Sarcoma Group. 
Eur. J. Cancer 29A (1993), pp. 143–144. 
12. J. Verweij, K. Krzemieniecki, T. Kok et al., Phase II study of miltefosine 
(hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult. An 
EORTC Soft Tissue and Bone Sarcoma Group Study. Eur. J. Cancer 29A (1993), 
pp. 208–209. 
13. J. Verweij, I. Judson, W. Steward et al.for the EORTC Soft Tissue and Bone 
Sarcoma Group, Phase II study with liposomal muramyl tripeptide 
phophatidylethanolamine (MTP/PE) in soft tissue sarcomas. Eur. J. Cancer 30A 
(1994), pp. 842–843. 
14. P.J. Woll, I. Judson, S.M. Lee et al., Temozolomide in adult patients with advanced 
soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma 
group. Eur. J. Cancer 35 (1999), pp. 410–412. 
15. H.J. Keizer, D. Crowther, O.S. Nielsen et al., EORTC Group phase II study of oral 
etoposide for pretreated soft tissue sarcoma. Sarcoma 1 (1997), pp. 99–101.  
16. J.Y. Blay, I. Judson, S. Rodenhuis et al., Phase II study of raltitrexed (Tomudex) for 
patients with advanced soft tissue sarcomas refractory to doxorubicin-containing 
regimens. Anticancer Drugs 10 (1999), pp. 873–877. 
17. Svancarova L, Blay JY, Judson I, et al. for the Soft Tissue and Bone Sarcoma 
Group. Phase II study on gemicitabine in advanced tissue sarcomas of the adult. 
Communication at the Annual Meeting of the Connective Tissue Oncology Society, 
Arlington, Virginia, MD, USA, October 21–23, 1999. 
18. M. Van Glabbeke, A.T. van Oosterom, J.W. Oosterhuis et al., Prognostic factors for 
the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 
2,185 patients treated with anthracycline-containing first-line regimens—a 
Progression free rate as the principal end point 
65 
European Organization for Research and Treatment of Cancer Soft Tissue and 
Bone Sarcoma Group study. J. Clin. Oncol. 17 (1999), pp. 150–157. 
19. S.J. Gwyther, O.S. Nielsen, I.R. Judson, M. Van Glabbeke and J. Verweij , 
Radiologist review versus group peer review of claimed responses in a phase II 
study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A 
study of the EORTC soft tissue and bone sarcoma group. Anticancer Drugs 11 
(2000), pp. 433–437. 
20. E.L. Kaplan and P. Meier , Non parametric estimation from incomplete observations. 
Am. Stat. Assoc. J. 53 (1958), pp. 457–481. 
21. M. Greenwood , The Natural Duration of Cancer. Reports on Public Health and 
Medical Subjects No. 33. , His Majesty's Stationary Office, London (1926). 
22. R. Peto and J. Peto , Asymptotically efficient rank invariant test procedures. J. R. 
Statis. Soc. A 135 (1972), pp. 185–207. 
23. D.R. Cox , Regression models and life tables. J. R. Statis. Soc. B 34 (1972), pp. 
187–200. 
24. S.J. Green and S. Dahlberg , Planned versus attained design in phase II clincial 
trials. Stat. Med. 11 (1992), pp. 853–862 
25. J. Bryant and R. Day , Incorporating toxicity considerations into the design of two-
stages phase II clinical trials. Biometrics 51 (1995), pp. 1372–1383. 
26. L.G. Ensign, E.A. Gehan, S.K. Douglas and P. Thall , An optimal three-stage design 
for phase II clinical trials. Stat. Med. 13 (1994), pp. 1727–1736. 
27. R. Mick and J.J. Crowley , Phase II clinical trial design for noncytotoxic anticancer 
agents for which time to disease progression is the primary end-point. Control Clin. 
Trials 21 (2000), pp. 343–359 

 Chapter VI  
 
  
Initial and late resistance to imatinib in advanced 
gastrointestinal stromal tumors are predicted by 
different prognostic factors:  
an EORTC-ISG-AGITG study 
Martine Van Glabbekea, Jaap Verweijb, Paolo G. Casalic, Axel Le 
Cesned, Peter Hohenbergere, Isabelle Ray-Coquardf, Marcus 
Schlemmerg, Allan T. van Oosteromh, David Goldsteini, Raf 
Scioth, Pancras C.W. Hogendoornj, Michelle Browna, Rossella 
Bertullic, Ian R. Judsonk 
a EORTC Data Center, Brussels; b Erasmus University Medical Center, Rotterdam; c Istituto 
Tumori, Milano, Italy; d Institut Gustave Roussy, Villejuif; e Charite Campus Buch, Robert 
Roessle Hospital, Berlin; f Centre Leon Berard, Lyon, France; g Klinikum Grosshadern; 
Munich, Germany; h University Hospital Gasthuisberg, Leuven, Belgium; i Prince of Wales 
Hospital, Randwick, Australia; j Leiden University Medical Center, Leiden, the Netherlands; 
k Royal Marsden Hospital, London, United Kingdom. 
Journal of Clinical Oncology 
Volume 23, Issue 24, August 2005, pages 5795-5804 
Chapter VI 
68 
Abstract 
PURPOSE: The aim of this study was to identify factors predicting initial and late resistance 
of GI stromal tumor (GIST) patients to imatinib and to document the dose-response 
relationship in the prognostic subgroups. This study is based on the European Organisation 
for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian 
Gastrointestinal Trials Group randomized trial comparing two doses of imatinib in advanced 
disease.  
PATIENTS AND METHODS: Initial resistance was defined as progression within 3 months 
of randomization, and late resistance was defined as progression beyond 3 months. 
Investigated cofactors include imatinib dose, age, sex, performance status, original disease 
site, site and size of lesions at trial entry, and baseline hematologic and biologic parameters.  
RESULTS: Initial resistance was recorded for 116 (12%) of 934 assessable patients and 
was independently predicted by the presence of lung and absence of liver metastases, low 
hemoglobin level, and high granulocyte count. Among 818 patients who were alive and 
progression free at 3 months, 347 subsequent progressions were recorded, and late 
resistance was independently predicted by high baseline granulocyte count, primary tumor 
outside of the stomach, large tumor size, and low initial imatinib dose. The impact of initial 
dose on late resistance was mainly significant in patients with a high baseline granulocyte 
count (> 5.109/L) and in patients with tumors of GI origin outside of the stomach and small 
intestine.  
CONCLUSION: Our study identifies patients for whom initial and/or long-term treatment 
needs to be improved and patients who require a high initial dose. Correlation of these 
results with immunohistochemistry and molecular parameters may further help to 
understand the biologic mechanisms of resistance.  
Introduction 
Soft tissue sarcomas represent 1% of adult malignancies and are a heterogeneous group of 
neoplasms whose only common denominator is their derivation from mesenchymal tissue. 
GI stromal tumors (GIST) are a subset of soft tissue sarcomas that were classified relatively 
recently. Their local treatment essentially consists of surgery. After the stage of resection, 
these tumors have proven to be insensitive to chemotherapy and radiotherapy [1]  
Imatinib is a small-molecule tyrosine kinase inhibitor that is active against BCR-ABL, KIT, 
and PDGFR. KIT is expressed in the vast majority of GISTs and is frequently mutated, 
leading to constitutive activation in these tumors. A European Organisation for Research 
and Treatment of Cancer (EORTC) phase I study [2] identified the highest feasible dose of 
imatinib to be 400 mg bid and indicated extensive activity of imatinib in GIST. Phase II 
studies showed activity at all doses tested (400 to 800 mg) [3,4]. Two large, randomized, 
phase III studies comparing doses of 400 mg once a day to 400 mg bid have confirmed the 
activity of imatinib in terms of progression-free survival and overall survival [5,6]. One of 
these studies has also documented a small but significant benefit with the high-dose 
regimen (400 mg bid) in terms of progression-free survival [5]. Finally, a randomized trial 
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from the French Sarcoma Group has demonstrated that imatinib therapy should be 
continued indefinitely, even after complete response [7]. 
Response of GIST to imatinib does not always result in an immediate decrease of the size 
of the lesions but, rather, in an initial inhibition of growth. Objective response (according to 
Response Evaluation Criteria in Solid Tumors [RECIST] criteria [8]) has been reported in 
approximately half of the patients, but time to onset varies largely among patients, and 
some responses have been first documented more than 1 year after start of therapy [5]. 
Therefore, response to imatinib is frequently defined as absence of progression at the time 
of the first formal disease evaluation (2 to 3 months after starting therapy), whereas 
progression at this time point is considered as initial or primary resistance. In patients who 
have experienced an initial stabilization, further progressions (or relapses) are considered 
late or secondary resistance. These two distinct mechanisms of drug resistance are 
reflected in progression-free survival curves by a rapid drop off at the time of first evaluation 
(initial resistance), followed by a slower continued decrease with a small hazard rate (late 
resistance). Analysis of genomic and biologic profiles has suggested that heterogeneous 
biologic mechanisms may be responsible for drug resistance; some of the mechanisms may 
already be present and active at baseline, and others may be activated later or result from 
acquisition of new mutations [9,10].  
The current article reports on an analysis of the clinical and biologic factors affecting initial 
and late resistance to imatinib, based on the data of the randomized trial jointly conducted 
by the EORTC, the Italian Sarcoma Group, and the Australasian Gastrointestinal Trials 
Group. This article also explores whether the recently reported advantage of high-dose 
imatinib [5] is homogeneous among prognostic subgroups.  
Patients and methods 
Eligibility Criteria 
Patients with histologically proven advanced and/or metastatic unresectable GIST 
characterized by c-KIT expression as assessed by polyclonal CD117 antibodies (Dako 
Cytomation, Glostrup, Denmark) were eligible for this trial. Any prior chemotherapy was 
accepted if discontinued for more than 4 weeks. Patients with measurable or 
nonmeasurable disease that was documented by conventional scan imaging or physical 
examination were eligible. Other eligibility criteria are described elsewhere [5]. Each 
participating institution obtained the approval of the competent ethical review board, and all 
patients gave written informed consent.  
Prestudy and Follow-Up Investigations 
Within 14 days before treatment, a physical examination was performed, CBC count and 
serum chemistry were assessed, and relevant computed tomography scans were 
performed for tumor assessment. Computed tomography scans were repeated after 2, 4, 
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and 6 months and every 3 months thereafter until progression of disease. The RECIST [8] 
method was used for evaluation of response and for documentation of progression.  
After completion of recruitment, paraffin-embedded tumor blocks were collected for a 
central pathology review and obtained for approximately half of the patients. Results of this 
review will be analyzed in the subgroup of patients for whom material is available and 
published separately.  
Treatment and Dose Modifications 
Patients were randomly assigned to receive either 400 mg administered orally once daily or 
400 mg bid. All patients were scheduled to continue treatment until disease progression or 
unacceptable toxicity. Dose modifications requested in case of toxicity are described in 
detail elsewhere [5] In case of disease progression in a patient randomly assigned to the 
400 mg once daily dose, a cross over to the 400 mg bid dose was allowed, regardless of the 
dose the patient was taking at the moment of progression.  
Statistical Analysis 
Initial resistance was defined as objective disease progression (according to RECIST [8]) 
within 3 months of randomization. The cutoff point was selected to include progressions 
documented at the first disease evaluation (after 2 months) but exclude progressions 
documented at the second disease evaluation (after 4 months). This end point was 
analyzed as a binary variable. Patients who either died in the absence of progression or 
who were lost to follow-up within 3 months of randomization were excluded from the 
analysis.  
Late resistance was analyzed as a time to event variable (time to objective progression) 
with a 3-month landmark period. Patients who experienced progression, died, or were lost 
to follow-up within 3 months of random assignment were excluded from this analysis. 
Patients who died in the absence of progression after 3 months were censored at the date 
of death.  
Cofactors investigated in the analysis included the initial daily dose of imatinib 
(randomized), age, sex, performance status at trial inclusion, primary site of disease 
(abdominal, stomach, small bowel, other GI, or other site), time since first GIST diagnosis, 
prior treatments for GIST (surgery, radiotherapy, and chemotherapy), site (primary tumor, 
liver metastases, or lung metastases) and size of lesions (diameter of the largest lesion) at 
the time of trial inclusion, and baseline hematologic and biologic parameters (WBCs, 
granulocytes, platelets, hemoglobin, creatinine, bilirubin, and albumin). Continuous 
variables were not recoded for building the prognostic models, but prognostic variables had 
to be recoded for drawing time to progression curves; in such cases, values close to 
quartiles were chosen as category cutoff points.  
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Both univariate and multivariate analyses used logistic regression (initial resistance) and 
Cox regression (late resistance) models. Factors found to be significant in the univariate 
analysis at the P = .05 level were subsequently included in a step-down multivariate model. 
Correlation between cofactors was measured by the Spearman rank correlation coefficient.  
Integrating results of the pathology review in this analysis would not have been possible 
without losing substantial power, but the analyses have been repeated on the subgroup of 
patients for whom the GIST histology had been externally confirmed as sensitivity analyses. 
The impact of significant prognostic factors is detailed in overall time to progression curves, 
which were estimated by the Kaplan-Meier method. All randomly assigned patients are 
included in those curves. The prognostic value of the randomly allocated initial imatinib 
dose has been subsequently explored in prognostic subgroups using the Wald test adjusted 
for repetitive testing.  
Results 
A total of 946 patients were included in the trial. At the time of this analysis, the median 
follow-up was 25 months (1- and 2-year follow-up rates, 98% and 58%, respectively). 
Comparisons of efficacy and toxicity parameters between therapeutic arms have been 
published elsewhere [5].  
Demographic Data 
Cofactors and their distribution are listed in Table 1. There was no major imbalance 
between the randomized arms 
Initial Resistance 
Among the 946 randomly assigned patients, 11 died within 3 months without evidence of 
progression (six patients from the 400 mg once daily arm and five from the 400 mg bid arm) 
because of toxicity (n = 2), infection (n = 3), hemorrhage (n = 3), severe diarrhea and 
vomiting (n = 1), and cardiac disease (n = 2). One ineligible patient (non-GIST, 400 mg 
once daily arm) was lost to follow-up. These 12 patients were excluded from the analysis. 
Among the 934 remaining patients, 116 (12%) experienced progression within 3 months 
(initially resistant).  
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Table VI-1: Distribution of cofactors 
Factor N % Randomized arm (N) 
   400 mg od. 400 mg bid. 
Age (years):     
Median / range 59 (18-91)   
< 40 72 7.6% 38 34 
40-50 176 18.6% 87 89 
50-60 228 24.1% 122 106 
60-70 282 29.8% 138 144 
> 70 188 19.9% 88 100 
Gender     
Male 573 61.3% 283 290 
Female 373 38.7% 190 183 
Performance score (WHO)     
0 436 46.1% 217 219 
1 383 40.5% 191 192 
2 92 9.7% 48 44 
3 35 3.7% 17 18 
Primary site of disease     
Gastrointestinal 793 84% 403 390 
Gastric 316 33.4% 159 157 
Small bowel 238 25.2% 124 114 
Abdominal 129 13.6% 58 71 
Other site 19 2.0% 11 8 
Unknown 5 0.5% 1 4 
Time since primary diagnosis (days)     
Median / range 338 (6–10092)   
< 12 months 493 52.11% 247 246 
12-24 months 157 16.60% 83 74 
> 24 months 296 31.29% 143 153 
Site of active disease     
   Primary tumor 316 33.40% 149 167 
   Liver 672 71.0% 329 343 
   Lung 80 8.5% 41 39 
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Factor N % Randomized arm (N) 
   400 mg od. 400 mg bid. 
Diameter of largest lesion (mm)     
   Median / range 78 (<20-800)   
   < 40 mm 203 21.5% 104 99 
40 – 80 mm 295 31.2% 150 145 
80 - 120 mm 225 23.8% 108 117 
> 120 mm 218 23.0% 109 109 
Unknown 5 0.5% 2 3 
Prior therapy     
Surgery 802 84.8% 410 392 
Radiotherapy 63 6.7% 26 37 
Chemotherapy 311 32.9% 156 155 
Baseline HGB (mmol/l)     
Median / range 7.9 (4.7-15.6)   
< 7 245 25.9 124 121 
7 – 8 245 25.9 127 118 
8 – 8.8 236 24.9 104 132 
> 8.8 220 23.3 118 102 
Baseline granulocytes (109/l)     
Median / range 4.8 (1.5-30.6)   
< 4 318 33.6 172 146 
4 – 5 196 20.7 99 97 
5 – 6.5 195 20.6 94 101 
> 6.5 237 25.1 108 129 
Baseline platelets (109/l)    
Median / range 297 (28-1245)   
Baseline creatinine (µmol/l)    
Median / range 79.6 (35-795.6)   
Baseline bilirubin (µmol/l)    
Median / range 10 (1.7-138.8)   
Baseline albumin (g/l)    
Median / range 39.2 (4.1-70.0)   
< 35 189 20.0 99 90 
35 – 39 181 19.1 86 95 
39 – 43 222 23.5 108 114 
> 43 155 16.4 79 76 
Unknown 199 21.0 101 98 
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The following prognostic factors of initial resistance were identified by univariate analysis (in 
order of significance): presence of lung metastases, low baseline hemoglobin level, high 
baseline granulocyte and platelet count, poor performance status, low baseline albumin 
level, absence of liver metastases, and short interval since the initial diagnosis of the 
disease (Table 2). None of the other cofactors showed any significant correlation with initial 
resistance.  
In the multivariate model, presence of lung metastases, low baseline hemoglobin level, and 
absence of liver metastases were highly significant adverse prognostic factors, and high 
baseline granulocyte count showed borderline significance (Table 2). Highly significant (P < 
.005) correlation coefficients (Spearman) were observed between baseline hemoglobin 
level and albumin level (r = 0.51), performance status (r = –0.32), platelet count (r = –0.26), 
granulocyte count (r = –0.092), and time since GIST diagnosis (r = 0.097), and between 
time since GIST diagnosis and liver metastases (r = 0.24). The logistic regression model 
was applied to 456 assessable patients with an independently confirmed GIST diagnosis. In 
this sensitivity analysis, only baseline hemoglobin level and granulocyte count retained a 
significant prognostic value. 
Table VI-2: Prognostic factors for initial resistance 
Factor Univariate analysis Multivariate model 
 Odd ratio P-value Odd-ratio P-value 
Lung metastases 0.323 < 0.0001 0.332 0.0001 
Baseline hemoglobin 1.421 < 0.0001 1.380 0.0004 
Baseline granulocytes 0.926 0.0049 0.935 0.0208 
Baseline platelets (/100) 0.845 0.0082   
Performance status 0.734 0.0079   
Baseline albumin 1.040 0.0186   
Liver metastases 1.611 0.0212 1.816 0.0055 
Time since GIST diagnosis (m) 1.297 0.0488   
Late Resistance 
The late resistance analysis is based on the 818 patients who where progression free and 
alive at 3 months (404 patients from the 400 mg once daily arm and 414 patients from the 
400 mg bid arm). A total of 347 progressions were subsequently recorded. Patients who 
died without evidence of progression because of toxicity (n = 3), drug- and disease-
unrelated events (n = 14), and unknown causes (n = 7) were censored at the date of death 
(10 patients from the 400 mg once daily arm and 14 patients from the 400 mg bid arm).  
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The following prognostic factors of late resistance were identified in the univariate analysis 
(in order of significance): high baseline granulocyte count, tumor size (largest diameter of 
the largest lesion), high baseline WBC count, poor performance status, nongastric primary 
tumor, small bowel primary tumor, low baseline albumin, prior chemotherapy, and random 
assignment to 400 mg once daily (Table 3). None of the other cofactors showed any 
significant correlation with late resistance.  
In the multivariate analysis, only four factors remained as significant independent factors of 
adverse prognosis: tumor size, high baseline granulocyte count, nongastric primary tumor, 
and random assignment to imatinib 400 mg once daily (Table 3). Highly significant (P < 
.0001) correlation coefficients (Spearman) were observed between baseline granulocyte 
count and WBC count (r = 0.90), tumor size (r = 0.33), performance status (r = 0.26), and 
albumin level (r = –0.24), and between tumor size and albumin level (r = –0.34) and 
performance status (r = 0.32). The final Cox regression model was also applied to the 
subgroup of 421 patients assessable for late resistance and with independent confirmation 
of the GIST diagnosis. The results of this sensitivity analysis were similar to the results 
observed for the whole cohort (with lower significance levels). 
Table VI-3: Prognostic factors for late resistance 
Factor Univariate analysis Multivariate model 
 Hazard ratio P-value Hazard ratio P-value 
Baseline granulocytes 1.064 < 0.0001 1.051 0.0009 
Diameter of the largest lesion 1.033 0.0001 1.023 0.0095 
Baseline white blood cells 1.051 0.0001   
Performance status 1.241 0.0014   
Gastric primary 0.712 0.0042 0.731 0.0088 
Bowel primary 1.385 0.0053   
Baseline albumin 0.976 0.0095   
Prior chemotherapy 1.298 0.0184   
Dose of imatinib  0.779 0.0202 0.754 0.0093 
Impact of the Most Significant Cofactors 
Liver and lung lesions. Initial resistance was documented in 96 (11%) of 857 patients 
without lung lesions, 10 (20%) of 50 patients with both lung and liver lesions, and 11 (41%) 
of 27 patients with lung but no liver lesions; in patients with externally confirmed GIST 
diagnosis, these progression rates were 8% (34 of 426 patients), 7% (two of 27 patients), 
and 0% (zero of 11 patients), respectively.  
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Baseline hemoglobin level. Figure 1 illustrates the increased initial resistance to imatinib 
in patients with a low baseline hemoglobin level (< 7 mmol/L or 11.27 mg/100 mL). After the 
first 3 months, the curves remained parallel, which is reflected in the lack of prognostic 
significance of this factor for late resistance.  
Figure VI-1: Progression-
free survival by 
hemoglobin level 
(mmol/l) 
 
 
Baseline granulocyte count. As shown in Figure 2, baseline granulocyte count slightly 
affected the initial drug resistance but largely affected the late resistance, which is 
substantially increased in patients with a baseline count greater than 5 x 109/L.  
Figure VI-2: 
Progression-free 
survival by 
granulocytes count 
(109/l) 
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Tumor size. Figure 3 illustrates the impact of tumor size on late resistance, which was 
mainly observed after 1 year of imatinib therapy and with an increasing failure rate in 
patients with large lesions (> 12 cm).  
Figure VI-3: Progression-
free survival by size of 
lesions 
(cm) 
 
 
Site of primary disease. Figure 4 shows the time to progression for tumors according to 
the site of primary disease. Patients with a disease of gastric origin have a better prognosis 
than patients with disease originating in the small bowel. In other subgroups, the limited 
sample size does not allow any formal comparison.  
Figure VI-4: 
Progression-free 
survival by site of 
primary disease 
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Competing risk. The aim of this study was to identify factors that could predict resistance 
to imatinib, and therefore, progression and time to progression have been chosen as 
primary end points. The competing risk of death in the absence of progression was ignored 
in the principal analyses (those patients were censored). However, in the same data set, a 
cumulative incidence analysis demonstrated a limited contribution (< 10%) of intercurrent 
deaths on progression-free survival [5]. We also performed a sensitivity analysis, 
considering all deaths as events, and obtained similar results. 
Table VI-4: Subgroup analysis 
 Number of cases Hazard ratio Wald test 
Subgroup Total Failures Estimate Confidence interval P-value 
All patients 946 463 0.801 0.667 0.961 0.017 
Bas. granulocytes < 5 109/l 514 207 0.874 0.665 1.15 0.3368 
Bas. granulocytes > 5 109/l 432 256 0.678 0.530 0.867 0.0020 
Largest diameter < 120 mm 728 336 0.793 0.640 0.982 0.0337 
Largest diameter > 120 mm 218 127 0.796 0.560 1.131 0.2025 
Stomach origin 316 131 0.836 0.593 1.179 0.3077 
Small bowel origin 238 130 1.025 0.726 1.446 0.8886 
Other GI origin 239 121 0.576 0.400 0.828 0.0029 
 
Subgroup analysis. The impact of the randomly allocated initial dose on time to 
progression was evaluated in the following subgroups: patients with a baseline granulocyte 
count greater or less than 5 x 109/L; patients with tumors smaller or larger than 12 cm; and 
patients with tumors of stomach origin, small bowel origin, or other GI origin (the number of 
events was too small in other subgroups). Table 4 lists the estimates of the hazard ratios, 
their 95% CIs, and the results of the Wald test for all subgroups.  
The advantage of the high initial dose of imatinib (in terms of time to progression) was 
statistically significant in the following two subgroups (overall P < .05, nominal P < .007): 
patients with a high (> 5 x 109/L) baseline granulocyte count (Fig 5) and patients with 
tumors of GI origin outside of stomach or small bowel (Fig 6). However, time to progression 
was not affected by the initial dose in patients with tumors of small bowel origin. 
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Figure VI-5: 
Progression free 
survival by dose level in 
patients with 
granulocytes >= 5 x 
109/L 
 
 
Figure VI-6: 
Progression free 
survival by dose level in 
patients with tumors of 
GI origin outside of the 
stomach or small bowel 
 
Discussion 
This prognostic factor analysis is based on the largest available series of patients with 
advanced or metastatic GIST who were consistently treated with imatinib, observed, and 
documented. The large sample size provides the appropriate power to identify with high 
confidence those factors that have an independent prognostic value.  
Information on all cofactors investigated in this study is usually available for individual 
patients in any clinical practice. Therefore, our results do provide immediate prognostic 
information for any patient diagnosed with advanced GIST and treated with imatinib. The 
results may guide decisions on individual treatment with imatinib and help to identify 
patients who require an initial high dose or who may not benefit from imatinib and for whom 
a different treatment approach may be considered.  
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The obtained prognostic models have not been validated. We could have built the 
prognostic models on a randomly selected subset of the data (a training sample) and 
validated the results on the remaining data (validation sample), but this would have reduced 
the power of the analyses. Because other large similar data series will become available, 
we elected to build the model on the whole study cohort, assuming that external validation 
will be carried out by independent groups and will provide more reliable results than internal 
validation.  
We have demonstrated that initial and late resistance to imatinib are predicted by different 
clinical and biologic factors. This is analogous to the existence of different competing 
mechanisms of resistance as identified on the basis of the analysis of genomic and 
molecular profiles [9,10]. Analysis of KIT and/or PDGF mutations will probably provide 
additional prognostic information, as already suggested [11]. However, nonbiomolecular 
mechanisms may also play a different role in the initial and late resistance setting.  
In the whole cohort of patients, initial resistance was predicted by the following four 
independent factors: baseline hemoglobin level, baseline granulocyte count, presence of 
lung metastases, and absence of liver metastases. The two last factors probably 
characterize a small proportion of misdiagnosed non-GIST patients. Sarcomas other than 
GIST have been proven to be unresponsive to imatinib [4]. Inclusion of a small proportion of 
non-GIST patients can largely affect the prognostic model for initial resistance because it is 
based on a 12% progression rate. This hypothesis is reinforced by the fact that those 
factors lose their significance when the analysis is restricted to the subgroup of patients with 
an external confirmation of the GIST diagnosis. Disease presentation with lung and/or 
without liver metastases should be an indication for external review of the pathologic 
diagnosis, but these factors probably do not affect resistance to imatinib in true GIST 
patients.  
Hemoglobin level has also been reported to be a prognostic factor in patients treated with 
imatinib for chronic myeloid leukemia [12,13]. In a previous EORTC study, low hemoglobin 
has been found to be correlated with pharmacokinetic parameters including small 
distribution volume, short half-life, low clearance (in L/h), and high area under the curve 
[14,15], and a first hypothesis is that hemoglobin level could affect the drug transport and 
delivery, resulting in insufficient intratumoral drug levels to inhibit disease proliferation in 
some patients with low hemoglobin. Indeed, small distribution volume (ie, high 
concentration) associated with short half-life may suggest that the drug remains in the blood 
instead of being distributed to organs (and to the tumor), which is in contrast to a high 
concentration associated with prolonged half-life that results from drug accumulation in the 
whole body (blood and tumor).  
The role of hemoglobin in drug transport is further suggested by the fact that significant 
amounts of imatinib could be quantified in the erythrocyte sediments of patients treated with 
the drug [16]. Erythrocyte loading was dose dependent in both volunteer and patient blood, 
and partition ratios of erythrocytes versus plasma ranged between 0.01 and 0.5. However, 
when patients have been treated with imatinib over prolonged periods of time, partition 
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ratios can increase beyond 3 (Prenen et al, personal communication, April 2004). Various 
anticancer agents are capable of inducing changes in their own partition ratios [17]; the 
implications for imatinib are subject of further investigations.  
Another hypothesis is that low hemoglobin reflects a more aggressive type of disease or a 
more advanced stage that is associated with mucosal ulceration and tumor bleeding and is 
less responsive to imatinib. Any other hypotheses suggesting that one of the molecular 
mechanisms of drug resistance either affects or is affected by hemoglobin levels could also 
explain this finding.  
The same kind of hypotheses can be made for granulocyte counts, which apparently affect 
both initial and late drug resistance. A high granulocyte count may reflect an inflammatory 
reaction induced by an aggressive type of tumor that tends to progress earlier. Molecular 
classification of patients with low hemoglobin levels and high granulocyte counts may help 
in understanding those findings.  
Late resistance to imatinib is independently predicted by the size of the lesions present at 
treatment start. Tumor size has also been reported as a prognostic factor for primary 
disease by several groups and, therefore, has been included in the definition of risk groups 
for GIST established by a consensus meeting [18]. In our study, tumor size did not affect 
initial resistance to the drug (as demonstrated both by the univariate and the multivariate 
analyses), suggesting that patients with an advanced stage of disease are initially 
responsive to imatinib (as opposed to what is observed with conventional chemotherapy in 
solid tumors). However, tumor size has a significant impact on late resistance, which seems 
to increase with time, suggesting correlation with a delayed mechanism of drug resistance. 
Patients with large lesions are probably more exposed to the risk of secondary mutations 
because of a higher likelihood of emergence of new clones, which explains the increasing 
risk of late resistance.  
According to our data, tumors of gastric origin tend to progress later than tumors of small 
bowel origin. This has also been reported for primary disease, and it has been suggested 
that the proportion of benign (as opposed to malignant) GISTs is higher in the stomach than 
in the small bowel [19] and that the mitotic index is highly site dependent [20]. Our model 
demonstrates that, in advanced disease, site of origin adds independent prognostic 
information to baseline granulocyte count and tumor size, but it still needs to be investigated 
whether this prognostic information is also independent of mitotic index.  
Despite the inclusion of 20% of patients older than the age of 70 years, age did not show 
any prognostic value for either initial or late resistance to imatinib, even in the univariate 
analysis. The same observation has been reported for chronic myeloid leukemia, with the 
conclusion that the adverse prognosis of elderly patients is generally related to the 
treatment rather than the intrinsic biology of the disease [21]. This statement is probably 
also true for GIST.  
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Finally, the subgroup analysis suggests that delayed resistance to imatinib in patients 
allocated to the high-dose regimen is mainly observed in patients with a high baseline 
granulocyte count (> 5 x 109/L) and in patients with a GI tumor origin outside of the stomach 
and the small bowel; our data do not suggest such an advantage in patients with tumors of 
small bowel origin. However, cross over from 400 mg once daily to 400 mg bid after 
progression has been shown to induce further disease stabilization in some patients [22] 
and only survival data will be able to demonstrate whether increasing the initial dose of 
imatinib results in a clinical benefit for all patients or subgroups of patients with advanced 
GIST.  
Our results may be used to identify patients for whom initial and long-term treatment should 
be improved. In particular, imatinib resistance can be delayed by increasing the initial dose 
in patients with high granulocyte counts and in patients with tumors of GI origin outside of 
the stomach and small bowel. These results may also be helpful in the investigation or 
confirmation of the different biologic mechanisms of drug resistance. Correlation of identified 
prognostic factors with immunohistochemical and molecular parameters could improve the 
knowledge of this disease.  
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Abstract 
The aim of this analysis is to identify prognostic factors of toxicity to imatinib treatment. 
It is based on 942 GIST patients randomized to receive imatinib at different doses [1]. The 
correlation between toxicities occurring with a CTC grade 2+ (non hematological) or 
grade 3+ (hematological) and imatinib dose, age, sex, performance status, original disease 
site, site and size of lesions at trial entry, baseline hematological and biological parameters 
was investigated. 
Anemia was correlated to dose and baseline hemoglobin level and neutropenia to baseline 
neutrophil count and hemoglobin level. 
The risk of non hematological toxicities was dose dependent and higher in females (edema, 
nausea, diarrhea), and in patients with advanced age (edema, rash fatigue), poor 
performance status (fatigue and nausea), prior chemotherapy (fatigue), tumor of identified 
gastro-intestinal origin (diarrhea) and small lesions (rash). 
We are proposing a multivariate risk calculator that can be used in the clinic for individual 
patients. 
Introduction 
GastroIntestinal Stromal Tumors (GIST) are a subset of soft tissue sarcomas classified 
relatively recently, that have proven to be insensitive to chemotherapy and radiotherapy [1]. 
Imatinib is a small molecule tyrosine kinase inhibitor active against BCR-ABL, KIT and 
PDGFR. KIT is expressed in the vast majority of GISTs and is frequently mutated leading to 
constitutive activation in these tumors. Treatment with imatinib has increased the two years 
survival expectation of patients with advanced or metastatic GIST from less than 20% to 
approximately 70% [2, 3] 
However, the optimal dose of imatininb for the treatment of GIST is still unclear. According 
to an EORTC phase I study, the highest feasible dose of imatinib in GIST is 400 mg bid [4]. 
One randomized phase II trial (400 mg od vs 300 bid) and one single arm phase II trial (400 
mg bid) have shown activity at all dose levels [5, 6]. The drug has been registered for the 
treatment of GIST at a daily dose of 400 mg. 
Formal comparison of the standard dose (400 mg od) versus the highest feasible dose (400 
mg bid) has been addressed in two large randomized phase III trials. These trials have not 
demonstrated a survival benefit, despite a small progression free survival advantage for the 
high dose arm [2, 3]. Exploratory analyses have suggested that the dose response 
relationship differs largely between prognostic subgroups [7, 8]. 
Although all trials report that the drug is well tolerated at the explored dose levels, a 
substantial proportion of dose reduction were reported in the two large randomized trials: 
10% and 44% respectively for the standard and the high dose arm (absolute proportion) in 
the SWOG study [9]; 13% and 49% (6 months cumulative incidence) in the 
EORTC/ISG/IGITG study (2); in this last study, respectively 32% and 50% of the patients 
experienced at least one CTC grade III or IV toxicity during therapy; anemia, edema, 
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fatigue, nausea, abdominal pain, diarrhea, neutropenia and rash were all recorded in more 
than 1/3 or the patients and all were dose dependent except for neutropenia and abdominal 
pain [2]. 
A similar toxicity profile has been reported in other imatinib trials, in GIST and other tumor 
types [4, 5, 6, 10, 11, 12]. 
The aim of the current study is to identify factors that influence the occurrence of the 
principal toxic events in GIST patients treated with imatinib, and to provide models to 
predict the probability of observing those toxicities in individual patients. 
Material and methods 
In the EORTC-ISG-AGITG phase III trial, 946 patients with advanced or metastatic GIST 
were randomized to be treated with imatinib at a dose of 400 mg od (standard dose arm) or 
400 mg bid (high dose arm). In case of progressive disease in the standard dose arm, a 
cross-over to 400 mg bid was scheduled. 
Eligibility criteria included a WHO performance score up to 3, normal hematological and 
renal function , and liver function tests within 2.5 time the upper normal value (or 5 times in 
case of liver metastases). Any prior therapy was allowed and there was no upper age limit. 
Toxicities were assessed weekly during the 2 first months of therapy, monthly up to 6 
months, and 3 monthly thereafter, using the Common Toxicity Criteria (CTC), version 2.0. 
Treatment had to be withheld until recovery in case of grade 2 non hematological and grade 
3 hematological toxicity; the dose had to be reduced in case of recurrence of those events, 
and in case of grade 3 non hematological toxicity. No dose reduction was required for 
anemia but transfusions and/or epoietin were allowed.  
Other eligibility criteria, evaluation criteria and efficacy results have been described 
elsewhere [2]. 
In the present study, we have analyzed the occurrence of the principal toxicities: grade 2 (or 
more) edema, fatigue, nausea, diarrhea and skin rash; grade 3 (or 4) anemia and 
neutropenia. Leucopenia and vomiting were not analyzed, because of their obvious 
correlation with neutropenia and nausea. Abdominal pain was not analyzed, because if was 
difficult to distinguish disease-related from treatment-related events.  
We first estimated the cumulative incidence of all events across time, using competing risk 
methods: per protocol discontinuations and dose escalations (because of progression) were 
considered as competing risks. 
For the prognostic factors analyses, we used logistic regression models to predict the 
absolute occurrences of events. Potential prognostic factors were first selected by 
univariate analysis. All factors significant at the 0.05 level in univariate logistic models were 
subsequently included in a multivariate regression model; factors significant at the 0.01 
level have been retained in the final model. 
For hemoglobin level and neutrophil counts, the correlation between the nadir and the initial 
value was further explored by linear regression. 
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The following variables were investigated as potential prognostic factors: age, sex, 
performance status, time since initial diagnosis of GIST, prior therapies (surgery, 
radiotherapy, chemotherapy), site of disease origin (stomach, bowel, other GI site, 
“abdominal” not further specified), and laboratory parameters at study entry (white blood 
cell count –WBC-, absolute neutrophil count –ANC-, platelets, hemoglobin, bilirubin, 
creatinine, albumin). 
An interactive risk calculator has subsequently been designed, on the basis of the final 
logistic models, using Microsoft Excel. Individual patient’s characteristics are entered by the 
user, and the calculator estimates the probability of each toxicity for this patient. This risk 
calculator can be downloaded from the web-site of the EORTC (www.eortc.be).  
To validate the final risk models (and the risk calculator), we have used the data of a phase 
I and a phase II study conducted in soft tissue sarcoma by the EORTC Soft Tissue and 
Bone Sarcoma Group [4, 6]. 
For each side effect, patients of the validation set have been classified in risk groups 
according to our models: estimated probability above 40%, between 20% and 40% and 
under 20% for edema and fatigue; estimated probability above 20% and under 20% for the 
other studied events. The observed occurrence of those events (and the estimated 95% 
confidence interval) has been tabulated for each risk group and compared to the model 
prediction. 
Results 
Duration of protocol therapy and follow-up 
The present analysis is based on the 942 patients who received at least one administration 
of imatinib. At the time of this analysis, 310 patients were still receiving the protocol therapy 
(without cross-over), but the median follow-up was 42 months and respectively 99%, 90% 
and 81% of the patients have been followed for 1, 2 and 3 years. At 1 year, only 27% of the 
patients had either discontinued protocol therapy or crossed-over to the high dose. 
Table VII-1: Distribution of CTC grades 
Grade 0 1 2 3 4 Total 
Neutropenia 547 (58.07) 179 (19.00) 149 (15.82) 41 (4.35) 26 (2.76) 942 
Anemia 65 (6.90) 438 (46.50) 313 (33.23) 89 (9.45) 37 (3.93) 942 
Edema 191 (20.28) 426 (45.22) 265 (28.13) 57 (6.05) 3 (0.32) 942 
Fatigue 238 (25.27) 369 (39.17) 249 (26.43) 84 (8.92) 2 (0.21) 942 
Diarrhea 434 (46.07) 334 (35.46) 137 (14.54) 36 (3.82) 1 (0.11) 942 
Nausea 411 (43.63) 347 (36.84) 155 (16.45) 29 (3.08) -- 942 
Rash 595 (63.16) 203 (21.55) 107 (11.36) 36 (3.82) 1 (0.11) 942 
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Description of toxicities 
The worst grade of reported toxicities are listed in table 1. 
The hematological toxicities included in this analysis are anemia (94% all grades / 13% 
grade 3 or higher) and neutropenia (42% / 7%), and the non hematological toxicities are 
edema (80% all grades / 35% grade 2 or higher), skin rash (37% / 15%), fatigue (75% / 
36%) and gastro-intestinal: nausea (56% / 20%) and diarrhea (54% / 18%). 
Cumulative incidence of events 
The cumulative incidence of the different types of toxities (overall, and for each therapeutic 
arm) is shown on figures 1, 2 and 3. 
At one year, the most frequent toxicities (edema and fatigue) had each occurred in 20% of 
the patients in the standard dose arm, and in respectively 42% and 37% of the patients in 
the high dose arm. 
Figure VII-1: Cumulative incidence of toxic events – All patients 
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Figure VII-2: Cumulative incidence of toxic events – 400 mg o.d. 
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Figure VII-3: Cumulative incidence of toxic events – 400 mg b.i.d. 
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Identification of risk factors 
Results of the univariate and multivariate prognostic factor analyses are summarized in 
table 2 for each toxicity. 
For anemia, only high dose and baseline low hemoglobin level were independently 
significant at the 0.01 level in the multivariate logistic model. The factor “low initial albumin 
level” added borderline significant information to this model (0.02). In linear regression 
models, nadir hemoglobin level was significantly correlated with dose (p<0.0001), initial 
hemoglobin level (p<0.0001) and initial albumin level (p=0.0001). 
In the multivariate logistic model the prognostic factors for neutropenia were baseline low 
ANC and low hemoglobin levels.. Neutropenia was not dose dependant (p=0.93).  In linear 
regression models, nadir ANC was only correlated with initial ANC. 
Independent prognostic factors for edema included high dose, advanced age, and female 
sex. An alternative model included high dose, female sex and baseline low albumin level 
(that is correlated with advanced age age). 
For rash, high dose, advanced age and small size of lesions turned out to be independent 
prognostic factors. As patients with large lesions progress earlier than patients with small 
lesions [7], we investigated whether, in patients with small lesions, the increased risk of 
developing rash could be explained by a longer exposure to imatinib: we first added the 
factor “total treatment duration” to the logistic model: this factor turned out to be significant, 
but the factor “size of lesions” kept its significance level. We also ran the model on the 
subset of patients treated for more than 6 months, and for more than 12 months: in both 
subgroups, the (small) size of the lesions remained a significant risk factor. 
For fatigue, high dose, advanced age, poor performance status and prior chemotherapy 
contributed to the final multivariate model. 
For nausea, high dose, female sex and poor performance status turned out to be 
independent prognostic factors. Small bowel origin adds information of borderline 
significance (p=0.012) to this model.  
Finally, the independent prognostic factors for diarrhea are high dose, female sex and 
identified gastro-intestinal site of primary disease. 
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Table VII-2: Results of the prognostic factors analyses 
 Anemia Neutropenia Fatigue 
 U M U M U M 
Dose level **** <0.0001   **** <0.0001 
Age     *** 0.0023 
Sex     *  
Perf. status ****    **** 0.0003 
Size of lesions **      
Prior radio.     **  
Prior chemo. *    ** 0.0007 
Initial HGB **** <0.0001 * 0.0022 ****  
Initial ALB ****    ***  
Initial ANC ***  *** <0.0001   
Initial WBC *  ****    
 
 Edema Rash Nausea Diarrhea 
 U M U M U M U M 
Dose level **** <0.0001 **** <0.0001 **** <0.0001 ** 0.0028 
Age *** 0.0011 **** <0.0001     
Sex **** <0.0001 *  **** <0.0001 * 0.0098 
Perf. Status *    **** <0.0001   
Primary : GI   *    * 0.0084 
Prim: abdomen   *    *  
Prim: stomach   *    *  
Prim: bowel     **    
Size of lesions   ** 0.0008     
Prior surgery     *    
Prior chemo.   **      
Initial HGB     **    
Initial ALB **    **    
Initial ANC     **    
Initial WBC     *    
U: univariate models; M: multivariate models; radio., radiotherapy; chemo., chemotherapy; prim., primary; HGB, 
hemoglobin; ALB, albumin; ANC, absolute neutrophils count; WBC, white blood cells 
Conventional coded significance levels are provided for the univariate analysis (*: p<0.05; **: p<0.01; ***: p<0.001; 
****: p<0.0001) while the exact significance levels are provided for all factors that remained in the final multivariate 
logistic models. 
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The final regression models (see coefficients in table 3) enable one to compute, for 
individual patients, a “risk score”, for each toxicity investigated in this study. These scores 
can be converted (by logistic transformation) into estimations of the probability to 
experience the toxicities. The models have also been programmed in an Excel spreadsheet 
that can be used in the clinic. Table 4 shows the obtained estimations for a few typical 
patients. 
Table VII-3: Multivariate models and risk calculator 
 Intercept  
Dose 
(1=400 od, 
2=400 bid) 
Age 
(in years) 
Sex 
(1=male, 
2=female) 
PS 
(WHO 
scale) 
GI origin 
(0=no, 
1=yes) 
Tumor 
size 
(in mm) 
Prior chemo. 
(0=no, 1=yes) 
Edema 4.54 - 1.1 - 0.0187 - 0.775     
Fatigue 3.48 - 0.924 - 0.0178  - 0.325   - 0.517 
Skin rash 4.77 - 0.954 - 0.0343    0.00631  
Nausea 4.64 - 0.96  - 0.963 - 0.404    
Diarrhea 3.53 - 0.514  - 0.441  - 0.723   
 
 Intercept  
Dose 
(1=400 od, 
2=400 bid) 
Baseline HGB 
(mmol/l) 
Baseline 
ANC 
(10**9/l) 
Anemia -1.94 - 0.993 0.715 0 
Neutropenia -1.618 0 0.36 0.292 
Table VII-4: Examples of result for individual patients 
Patients characteristics Dose Probability of grade 3 (or 4) toxicity (%) 
HGB (mmol/l) ANC (10**9/l) (mg/day) Anemia Neutropenia 
400 6 6 
8 5 
800 14 6 
400 20 12 
6 5 
800 41 12 
400 3 4 
9 5 
800 8 4 
400 6 1 
8 3 
800 14 11 
400 6 2 
8 9 
800 14 2 
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Patients characteristics Dose Probability of grade 2 (or higher) toxicity (%) 
Age 
(years) 
Sex 
PS 
(WHO) 
Prior 
chemo. 
Lesion 
size 
(mm) 
GI 
origin 
(mg/ 
day) 
Edema 
Fati-
gue 
Skin 
rash 
Nau-
sea 
Diar-
rhea. 
400 18 24 9 9 14 
60 M 1 No 80 Yes 
800 39 44 21 21 21 
400 13 18 5 9 14 
40 M 1 No 80 Yes 
800 31 36 12 21 21 
400 22 29 15 9 14 
75 M 1 No 80 Yes 
800 46 51 31 21 21 
400 32 24 9 21 20 
60 F 1 No 80 Yes 
800 58 44 21 40 29 
400 18 18 9 6 14 
60 M 0 No 80 Yes 
800 39 36 21 15 21 
400 18 30 9 13 14 
60 M 2 No 80 Yes 
800 39 52 21 28 21 
400 18 34 9 9 14 
60 M 1 Yes 80 Yes 
800 39 57 21 21 21 
400 18 24 13 9 14 
60 M 1 No 25 Yes 
800 39 44 28 21 21 
400 18 24 5 9 14 
60 M 1 No 200 Yes 
800 39 44 11 21 21 
400 18 24 9 9 7 
60 M 1 No 80 No 
800 39 44 21 21 11 
 
We have validated this model using data of 91 patients with advanced or metastatic 
sarcoma treated with imatinib at doses ranging from 400 to 1000 mg/day. We have used 
the calculator to estimate the probability of observing toxicities for all patients included in 
this data set, and accordingly classified patients in risk groups. The proportion of toxicities 
really observed in all risk groups is shown in table 5.  
The observed proportion of toxicities corresponds to the model for all except 3 groups, 
where the estimated 95% confidence interval still overlaps with the predicted chance range. 
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Table VII-5: Results of the validation 
Risk estimated by the model  > 40% 20-40 % < 20% TOTAL 
Nr cases 43 42 6 91 
Edema 
Observed events 18 (41.9%) 18 (42.9%)* 0 36 (39.6%) 
Nr cases 60 30 1 91 
Fatigue 
Observed events 38 (63.3%) 10 (33.3%) 0 48 (52.7%) 
* 95% confidence interval: 27.7% - 59% 
Risk estimated by the model  > 20% < 20% TOTAL 
Nr cases 33 58 91 
Skin rash 
Observed events 15 (45.5%) 10 (17.2%) 25 (27.5%) 
Nr cases 62 29 91 
Nausea 
Observed events 21 (33.9%) 10 (34.5%)* 31 (34.1%) 
Nr cases 38 53 91 
Diarrhea 
Observed events 16 (42.1%) 11 (20.8%)** 27 (29.7%) 
Nr cases 24 67 91 
Anemia 
Observed events 7 (29.2%) 9 (13.4%) 16 (17.6%) 
Nr cases 1 90 91 
Neutropenia 
Observed events 0 12 (13.3%) 12 (13.2%) 
* 95% confidence interval: 17.9% - 54.3%; ** 95% confidence interval: 10.8% - 34.1% 
 
Discussion 
Analyses of toxicity of cancer therapies generally focus on CTC grade 3 or 4 (grade 4 for 
hematological toxicities).  In this study, we have analyzed the occurrence of grade 2 (or 
higher) non hematological toxicities and grade 3 (or more) hematological toxicities. 
A randomized trial from French Sarcoma Group has demonstrated that imatinib therapy 
should be continued indefinitely, even after complete response [13].Toxicities generally 
considered as acceptable for a limited treatment period may be less unacceptable for a 
chronic therapy, and lead to dose reductions or even treatment discontinuation. A previous 
analysis has shown that the proportion of patients with toxicity seems to decrease with time 
[1] and toxicities do not substantially increase when the dose is escalated from 400 mg od 
to 400 mg bid [16]. This may be explained by an increase of the drug clearance and a 
subsequent lower drug exposure [15]. However, not all patients recover when the dose is 
maintained and recurrence of toxicity has been documented after rechallenging the patient 
at the same dose [22]. 
More than 75% of the toxicities occurred within 1 year of treatment start and at least 1 year 
of follow-up is available for 99% of the patients. We do therefore consider our data as 
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mature, despite the fact that 310 of the 942 evaluable patients were still receiving protocol 
therapy. 
For the identification of prognostic factors, we neglected the possible impact of treatment 
discontinuations, but simply analyzed the occurrences of toxicities as binary variables, 
using logistic regression models. Unfortunately, no reliable and easily interpretable 
multivariate model is available for this competing risk situation. As 73% of the patients were 
still receiving protocol therapy one year after treatment start, it is unlikely that this choice is 
influencing the conclusions, especially as the variables that we have identified as 
prognostic factors for toxicity (age, sex, performance status, prior chemotherapy) do 
generally not influence progression free survival, the principal cause of treatment 
discontinuations [7]. 
Our results confirm that all investigated toxicities are highly dose dependent (p=0.005 for 
diarrhea, and p<0.0001 for all other toxicities), with the exception of neutropenia (p=0.93). 
For GIST patients, this was previously reported in a phase I dose escalation study [4], in a 
randomized phase II study [5] and in two randomized phase III studies [2, 3]. No 
randomized data are available for leukemia, but most series also suggest that toxicities are 
dose dependent: nausea, edema, diarrhea and rash [17], nausea, edema and diarrhea [18] 
and anemia [19]. In only one Philadelphia chromosome-positive chronic phase CML study 
of 144 cases [20], toxicities were not more frequent with high dose imatinib (400 mg bid) 
than in an historical series of 50 patients treated at standard dose (400 mg od), but those 
data should be interpreted with caution, because of the limited sample size and the use of 
historical controls. 
Neutropenia was completely dose independent in our study. This was also the case in 
phase I CML trials [17, 18]. It should be noted that the reported frequency of neutropenia 
largely differed between diseases: 7% grade 3-4 in our study, as compared with 62%, 59%, 
35% and 13% in large CML phase II trials, for decreasing stages of the disease respectively 
[11]. 
Risk factors for toxicity have not been previous explored in patients treated with imatinib for 
GIST, but some data are available from CML studies: the cumulated data of 3 phase II trials 
(532 cases) has been analyzed by Hensley [11] and Cohen [12], while Cortes [19] focused 
on anemia in a partially overlapping population (338 cases); Valeyrie [22] has studied 
cutaneous toxicities on a smaller series (54 cases) of patients treated for Philadelphia 
chromosome positive leukemia. 
Advanced age was reported as a significant risk factor for edema [11, 12] and anemia [19], 
and female sex as a significant risk factor for neutropenia, edema, nausea and fatigue [12], 
for rash [12, 22] and for anemia [19]. For non hematological side effects, we observed the 
same correlations (but sex dropped out of the multivariate model for fatigue and rash). 
Hensley has identified a correlation between drug exposure (steady state plasma 
concentration) and edema, but this factor was not independent from age and sex [11]. In a 
GIST study, Judson has observed that the drug clearance was lower and, subsequently, 
the area under the concentration curve higher for female patients, and for patients with low 
baseline albumin levels [14]. Those two findings suggest that drug exposure may be higher 
in female and/or elderly patients, who are consequently at a higher risk of toxicity. 
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For anemia and neutropenia, we did not find any correlation with age and sex, but only with 
low baseline hemoglobin and neutrophils levels. AUC has also been reported to be higher 
in patients with baseline low hemoglobin level [14] and high granulocytes counts [15], so 
the prognostic value of baseline hemoglobin for neutropenia may be explained by a higher 
drug exposure and a possible role of hemoglobin in drug transport and delivery [23, 24]. 
The increased risk of fatigue and nausea in patients with a poor performance status, the 
increased risk of fatigue for patients who have received prior chemotherapy and the 
increased risk of diarrhea in patients with tumors of identified gastro-intestinal origin has not 
been previously reported, but the last two factors could obviously not be explored in 
leukemia patients. 
More surprising is the decreased risk of skin rash for patients with large lesions, and for 
patients with prior chemotherapy; the last factor dropped out of the multivariate model 
because it was associated with age (patients above 60 years old were less frequently pre-
treated). As progression tends to occur earlier in patients with large lesions [7], we 
investigated whether the decreased risk of rash could be due to a limited duration of the 
drug exposure: this hypothesis had to be rejected, as tumor size remained a significant risk 
factor when treatment duration was entered in the model, or when patients with short 
treatment duration (<6 or <12 months) were excluded from the dataset.  In the CML studies 
a higher risk of toxicity was reported for patients with advanced disease, but the dose of 
imatinib may have been an important confounding factor [10, 11]. So far, we are unable to 
explain this correlation. 
We are proposing to estimate the probability of experiencing toxicities for individual patients 
on the basis of the final logistic models issued from this analysis. The coefficients of all 
models are included in table 3, and we are also proposing an interactive risk calculator 
(using the same coefficients), programmed in Excel. This simple tool can be used in clinical 
practice to customize treatment for individual patients. 
Those models have been estimated on the basis of the largest available series of GIST 
patients treated with imatinib. They has been validated on the basis of a small series of 91 
sarcoma patients treated at doses ranging from 400 mg to 1000 mg. Results of those 
validation tests are generally good (except for the underestimation of edema and nausea in 
the low risk groups), considering the limited sample size of the validation set. In our 
validation data set, the occurrence of edema was not correlated with sex, which can explain 
the discrepancy with our edema model. We expect to be able to further validate our models 
when data from larger series of patients become available. 
In conclusion, this study has identified factors that can potentially increase the risk of 
encountering toxicities in patients with advanced or metastatic GIST treated with imatininb. 
Based on those results, we propose a simple tool to calculate the risk of the principal toxic 
events for individual patients. 
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A general description of soft tissue sarcomas and their treatments is given in Chapter 1.  
The chapter also provides an introduction to the work on prognostic factors that is described 
in this thesis. 
In chapter 2, we have identified the characteristics of the patients (and of their disease) 
influencing the survival expectation and the probability to respond to first line chemotherapy 
for advanced disease. Not surprisingly, advanced age is an adverse prognostic factor of 
survival and response to therapy. Poor performance adversely affects survival but not the 
probability of response to first line therapy. The number and size of the lesions does not 
affect response and neither survival, at the time of diagnosis of advanced disease. The 
survival prognosis is more favorable if the sarcoma was diagnosed at least 2 years before 
chemotherapy was needed. Patients who were initially diagnosed with low grade disease 
have a longer survival expectation, despite the fact that they respond less frequently to 
chemotherapy; and they are probably not appropriate candidates to test the activity of new 
drugs, especially if response is used as principal end-point. 
The presence of liver metastases shortens the survival expectation, and decreases the 
probability of response. This suggested that either liver metastases are less chemo-
sensitive, or that they represent an even more advanced stage of the disease, but 
alternatively, we could initially also not exclude that most of the patients with liver 
metastases could have had GIST, a histological sub-type known not to respond to 
chemotherapy. In an updated analysis, we excluded possible GIST patients and still 
observed a disadvantage in survival and response in patients with liver metastases. We 
concluded that the adverse prognostic effect of liver metastases in the series is not fully 
explained by the presence of GIST. 
For randomized trials allowing entrance of patients with the various tumor types, the 
prognostic factors identified in this work should be used to stratify the treatment allocation 
(correcting the randomization process to ensure that those factors are evenly distributed 
between the two randomized arms). 
The probability of response and the survival expectation is not the same for the different 
histological subtypes, but baseline characteristics (age, tumor grade and liver metastases) 
also differ between those groups. Knowing the exact subtype does generally not improve 
the estimation of the response probability and survival expectation if the other factors are 
already taken into account, except for liposarcoma for which the probability for response is 
higher. However, the estimation of response and survival for the different subtypes provides 
useful references for future histology specific trials. 
In chapter 3, we have observed that 8% of the patients treated with a first chemotherapy 
for advanced disease are still alive after 5 years, which contrasts with the median survival of 
approximately one year in this population. 
Those long term survivors more frequently are women, patients with a good initial physical 
performance, with a low grade tumor, and/or patients who had a complete response to 
treatment (complete disappearance of all lesions and of all cancer symptoms). A few deaths 
were still observed after 5 years, mostly in patients who had not responded to initial 
chemotherapy. 
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We concluded that a small proportion of patients with advanced soft tissue sarcoma can be 
cured with chemotherapy, in contract with the general opinion that systemic chemotherapy 
for advanced disease can only be palliative. 
In chapter 4, we have investigated the possibility to use of the new “Response Evaluation 
Criteria for Solid Tumors” (RECIST) for soft tissue sarcoma. We retrospectively evaluated 
the results of the STBSG phase II study on the drug “ET-743” (now known as trabectedin) 
using RECIST instead of the WHO criteria used for the primary evaluation of the study 
results (in accordance with the protocol). This study was specifically designed to validate 
the new criteria, and objective measurements of all target lesions were reported on the data 
forms for the two methods. 
There were only minor differences between the two evaluations, and the conclusions of the 
study would not have been modified by the use of RECIST. This validates the use of 
RECIST in soft tissue sarcoma, and the STBSG subsequently adopted the new criteria for 
phase II studies on cytotoxic drugs. 
In chapter 5, we are proposing to use the progression free status of the patient at a fixed 
time point as primary end-point for phase II trials in soft tissue sarcoma. We have estimated 
the proportion of patients with stable disease (no measured increase in the size of the 
lesions) 3 and 6 months after start of chemotherapies in various groups of patients. 
After failure of a first line chemotherapy regimen, 39% of the patients treated with agents 
known to induce responses (ifosfamide and dacarbazine) had a stable disease at 3 months, 
while this figure was only 21% for patients treated with investigational agents that ultimately 
failed to induce responses. We concluded that progression free rate at 3 months is an 
appropriate criterium to evaluate the activity of a new drug used as second or third line 
therapy. The estimation of the progression free rates was precise enough to be used as 
reference values for the design of phase II trials. 
For patients treated with a first line chemotherapy regimen, the size of the database was 
sufficient to provide specific reference values for the principal histological subtypes (for 
active combinations only). Those references values have become extremely useful for the 
evaluation of targeted therapies, which are not expected to be cytotoxic. 
In chapter 6, we investigated prognostic factors of resistance to imatinib mesylate in 
patients with advanced GIST. We have analyzed the data of the phase III study comparing 
the outcome of two daily doses of imatinib. The impressive activity of this drug in this 
disease is translated by an interruption of the tumor growth in most patients. However, a 
small proportion of the patients appear to be completely insensitive to the drug (early 
resistant), and progress rapidly. Patients with initial disease stabilization may relapse later; 
it is believed that tumor regrowth (late resistance) is induced by a different biological 
mechanism than the initial disease. 
The proportion of “progression free” patients drops rapidly during the first 3 months, and 
more slowly thereafter. Based on this observation, we have considered progression within 3 
months of start of therapy as “early resistance” and progression after 3 months as “late 
resistance”. We have independently analyzed prognostic factors for early and late 
resistance. 
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Early resistant patients were those with an initial low hemoglobin and high granulocyte 
count. Prognostic factors for late resistance were high initial granulocyte count, large 
lesions and original localization of the disease outside of the stomach. We suggested that 
hemoglobin level could have an impact on the transport of the drug from the blood to the 
tumor, that the biological mechanism of tumor growth could vary between tumors of 
different anatomical origin, and that large tumors could more frequently induce secondary 
mutations that would lead to tumor regrowth. 
Early resistance was independent of the daily dose, but late resistance was dose 
dependent, particularly in some of the prognostic subgroups. A subsequent analysis of the 
genetic mutations in the original tumor blocks showed large correlations between the types 
of mutations and the original localization of the disease. 
In chapter 7, based on the data of the same study, we have identified patient’s 
characteristics that influenced the occurrence of the principal toxicities. Women and 
patients with advanced age or poor performance status have generally a higher chance to 
experience edema, skin rash, fatigue, nausea and/or diarrhea during treatment with imatinib 
mesylate, but those factors do not influence the probability of all toxicities with the same 
magnitude. Additionally, diarrhea is more frequent in patients with a tumor originally located 
in the gastro-intestinal tract, skin rash in patients with small lesions, and fatigue in patients 
who have received prior chemotherapy. All toxicities are highly dose dependant (except 
neutropenia), but, again, the impact of the dose is not of the same magnitude for all 
toxicities. 
We have subsequently generated multivariate models to estimates the probability of the 
different toxicities for individual patients. Those complex models have been integrated into 
an Excell program that can be used in clinical practice.  
Those models have been validated with the data of the prior phase I / II study of imatinib 
mesylate conducted by the STBSG. 
Future perspectives 
Based on the exploration of the databases accumulated by the EORTC STBSG, the studies 
described in this thesis will contribute to: 
Better prediction of the outcome of available treatments for advanced soft tissue sarcoma 
and GIST, on the basis of patients and disease characteristics at treatment start:  
• Response probability and survival expectation for patients receiving doxorubicin 
based combinations as fist line therapy for advanced disease 
• Progression free rate for patients treated with active and inactive drugs after failure 
to first line therapy, and for individual histological subtypes in first line therapy 
• Early and late resistance to imatinib mesylate for patients with advanced GIST 
• Occurrence of the principal toxicities of imatinib mesylate for patients with 
advanced GIST 
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Generation or confirmation of hypotheses that will contribute to the understanding of those 
diseases: 
• Liver metastases from soft tissue sarcoma are either relatively insensitive to 
chemotherapy, or characterize an even more advanced stage of disease that is 
beyond chemo-sensitivity 
• Systemic chemotherapy is curative for a small proportion of patients with 
advanced soft tissue sarcoma 
• Hemoglobin may play a significant role in the transport of imatinib mesylate from 
the blood to the tumor 
• The biological mechanisms of tumor growth in GIST are not evenly distributed 
between tumors of different anatomical origin 
• Large GIST lesions could more frequently induce secondary mutations 
Optimization of the design of future clinical trials to appropriately explore new potential 
systematic treatments: 
• Trials comparing first line chemotherapy regimen should be stratified by age 
group, histological grade of disease and presence of liver metastases 
• Patients with low grade tumors should not be included in trials using response to 
therapy as the primary end-point 
• RECIST provide an appropriate primary end-point for testing cytotoxic drugs in soft 
tissue sarcoma 
• Progression free rate at 3 months is an appropriate end-point for testing cytostatic 
drugs and targeted therapies in soft tissue sarcoma; appropriate reference values 
are available for this end-point 
• Reference values are also provided to conduct histology specific phase II trials in 
first line therapy with targeted therapies. The favorable toxicity profile of these 
agents and the limited activity of chemotherapy can justify such trials. 
In the first part of this thesis, we have focused on patients treated with doxorubicin 
containing combinations as first line therapy for advanced soft tissue sacoma. Ifosfamide is 
the second active drug in this disease, and a large number of patients treated with this drug 
are now documented in our database. We will investigate whether the prognostic factors for 
response and survival are the same in this population, which may help to select the most 
appropriate first line therapy for future patients. 
RECIST is certainly not an appropriate end-point for the screening of new targeted 
therapies in GIST. Progression free rate at 3 months may be an appropriate alternative, but 
we will explore the actual measurements of the disease and investigate whether they can 
provide more reliable and specific criteria to document early resistance. 
It has been demonstrated that resistance of GIST to imatinb could be overcome by 
increasing the daily dose; prognostic factors of first objective progression may ultimately not 
affect overall survival. When a sufficient follow-up will be available, we will identify 
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prognostic factors of survival and compare them to the prognostic factors of early and late 
progression. 
Prognostic factors of early and late resistance in GIST have not yet been validated and 
prognostic factors of toxicity have been validated in a very small dataset. A second study of 
imatinib in GIST was conducted in US and Canada, using a nearly identical clinical trial 
protocol. After publication of the results of this second study, we are expecting to be able to 
use its data to confirm our models. 
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Een algemene beschrijving van weke delen sarcomen en hun behandelingen word 
gegeven in Hoofdstuk 1. Dit hoofdstuk geeft ook een inleiding tot het werk over 
prognostische factoren dat in dit proefschrift beschreven is. 
In Hoofdstuk 2 hebben we de kenmerken van patiënten (en hun ziekte) geïdentificeerd die 
de overlevingkans en de kans op respons op eerste lijns behandeling voor vergevorderde 
ziekte (niet meer volledig chirurgisch te verwijderen of uitgezaaid) beïnvloeden. Zoals 
verwacht, is gevorderde leeftijd een ongunstige prognostische factor voor overleving en 
voor respons op behandeling. Slechte klinische conditie heeft een ongunstige invloed op 
overleving maar niet op de kans op respons op eerste lijns behandeling. Het aantal en de 
grootte van de kwaadaardige lesies heeft geen invloed op respons of overleving. De 
overlevingskans is beter als het sarcoom meer dan twee jaar voorafgaand aan de 
chemotherapie gediagnosticeerd wordt. Patiënten met een tumor van lage 
maligniteidsgraad hebben een langere overlevingskans, hoewel ze minder vaak goed op 
chemotherapie reageren; ze zijn misschien geen goede kandidaten om de activiteit van 
nieuwe geneesmiddelen te testen, vooral als respons op behandeling gebruikt wordt als 
voornaamste eindpunt. 
De aanwezigheid van levermetastasen vermindert de overlevingskans, en de kans op 
respons. Dit suggereert dat levermetastasen minder chemosensitief zijn, ofwel dat ze een 
kenmerk zijn van een vergevorderd stadium van de ziekte, maar we konden oorspronkelijk 
niet uitsluiten dat de patiënten met levermetastasen meestal gastrointestinale stroma 
tumoren (GIST) hadden, een bekend chemotherapieresistent histologisch subtype 
sarcoom. Daarom zijn in een latere analyse alle mogelijke GIST patiënten uitgesloten, en 
desondanks bleef er een slechtere overleving en respons bij patiënten met 
levermetastasen. Wij concluderen dat de tegenstrijdige prognostische invloed van 
levermetastasen in onze data niet volledig door de aanwezigheid van GIST verklaard wordt.  
Voor gerandomiseerde klinische studies die insluiten van  de verschillende histologische 
subtypen toestaan, zouden de prognostische factoren die we hebben geïdentificeerd in 
onze studie, gebruikt kunnen worden als stratificatiefactoren voor behandelingsallocatie 
(om zo het randomisatie proces te verbeteren en zeker te zijn dat deze factoren gelijk 
verdeeld zijn tussen de gerandomiseerde groepen). 
De kans op respons en de overlevingsverwachting zijn niet identiek voor de verschillende 
histopathologische subtypen, maar de basis kenmerken leeftijd, tumorgraad en 
levermetastasen verschillen ook tussen deze groepen. Kennis van het preciese subtype 
verbetert gewoonlijk de inschatting van de overlevingskans en kans op respons overigens 
niet, als de andere prognostische factoren al bekend zijn, met uitgezondering van 
liposarcomen die een hogere responskans hebben. Maar de inschatting van responskans 
en overlevingkans voor verschillende histologische subgroepen verschaft een goede 
referentie voor toekomstige klinische onderzoeken bij gedefinieerde histologische 
subgroepen. 
In het onderzoek beschreven in Hoofdstuk 3 vonden wij dat 8% van de patiënten die 
behandeld werden met een eerste lijn chemotherapie voor vergevorderde ziekte na 5 jaar 
nog in leven waren, terwijl de gemiddelde overleving slechtsongeveer 1 jaar is in deze 
populatie. 
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Deze lange termijn overlevers zijn vaker vrouwen, patiënten met een goede initieele 
klinische conditie, een lage tumorgraad, en/of patiënten die een complete respons hadden 
op behandeling (verdwijnen van alle lesies en kanker symptomen). Sommige patienten 
overleden meer dan 5 jaar na de behandeling. Meestal betrof dit patiënten met een 
partieele respons of de initieele chemotherapie. 
Daaruit hebben we kunnen afleiden dat een klein aantal van de patiënten met 
vergevorderde ziekte kan genezen worden met chemotherapie, in tegenstelling tot de 
algemeen gehandteerde veronderstelling dat systemische behandeling voor vergevorderde 
ziekte alleen palliatief zal zijn. 
In Hoofdstuk 4, hebben we het mogelijk gebruik van de nieuwe “Response Evaluation 
Criteria for Solid Tumors” (RECIST) voor weke delen sarcomen onderzocht. We hebben 
daarvoor de STBSG fase II studie met het geneesmiddel “ET-743” (nu ook bekend als 
trabectedin) retrospectief geanalyseerd, en RECIST gebruikt in plaats van de WHO criteria 
die waren gebruikt voor de oorspronkelijke evaluatie. Deze studie was speciaal ontworpen 
om de nieuwe criteria te valideren, en objectieve metingen van alle doel lesies met beide 
methoden waren verzameld op de studie formulieren. 
Er waren maar kleine verschillen tussen beide evaluaties, en de conclusies van het 
onderzoek zouden niet verschillend zijn als de RECIST methode gebruikt zou zijn. 
Daarmee kunnen we het gebruik van RECIST voor weke delen sarcomen valideren. De 
STBSG heeft dus de nieuwe criteria aanvaard voor toekomstige fase II studies met 
celdelingremmende geneesmiddelen (cytostatica). 
In Hoofdstuk 5 stellen we voor de progressievrije status op een bepaald tijdpunt als primair 
eindpunt te gebruiken in fase II studies bij weke delen sarcomen. We hebben percentage 
patiënten met stabiele ziekte (zonder toename van de omvang van de lesies) 3 en 6 
maanden na het begin van chemotherapie geschat  in verschillende patiëntengroepen.  
Na het niet meer werken van de eerste lijn chemotherapie combinatie, had 39% van de 
patiënten die behandeld werden met een geneesmiddel dat bekend actief is bij weke delen 
sarcoom (ifosfamide en dacarbazine) een stabiele ziekte na 3 maanden, terwijl dit slechts 
21% was voor patiënten die behandeld werden met nieuwe geneesmiddelen die achteraf 
geen activiteit bleken te hebben. Wij concluderen dat stabiele ziekte na 3 maanden een 
goed eindpunt is om de activiteit van tweede of derde lijn behandeling te evalueren. De 
schatting van het percentage progressievrije patiënten was nauwkeurig genoeg om gebruikt 
te worden als referentiewaarde voor het ontwerpen van fase II studies. 
Voor patiënten behandeld met eerste lijn  (aciteve) chemotherapie combinaties, was de 
steekproefgrootte van de databank voldoende om specifieke referentiewaarden te geven 
voor de meeste histologische subtypes. Deze referentiewaarden zijn nu heel nuttig voor de 
evaluatie van nieuwe, moleculair doelgerichte geneesmiddelen, die zijn niet celdodend 
(cytotoxic) zijn. 
In Hoofdstuk 6 hebben we prognostiche factoren onderzocht voor resistentie op imatinib 
mesylaat behandeling van patiënten met vergevorderde GIST. We hebben de data van een 
fase III studie bestudeerd, die het effect van twee verschillende doses imatinib vergeleek. 
De indrukwekkende werkzaamheid van dit geneesmiddel is leidt tot een onmiddellijke 
stopzetting van de tumorgroei bij de meeste patiënten. Maar een klein gedeelte van GIST 
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patiënten schijnen totaal resistent te zijn tot dit geneesmiddel (vroeg-resistent) en tonen 
een snelle progressie. Patiënten met een aanvankelijk goede respons,kunnen later 
recidiveren; men denkt dat deze recidieven (late resistentie) veroorzaakt woren door een 
verschillend biologisch mechanisme dan vroege resistentie.  
Het percentage van progressievrije patiënten vermindert snel gedurende de eerste 3 
maanden, en daarna veel langzamer. Op grond van deze observatie hebben we 
ziekteprogressie gedurende de 3 eerste maanden als “vroege resistentie” geclassificeerd, 
en ziekteprogressie na de 3 eerste maanden als “late resistentie”. We hebben 
prognostische factoren van vroege- en late resistentie onafhankelijk onderzocht. 
Vroeg resistente patiënten hadden een aanvankelijk laag hemoglobine gehalte en een hoog 
granulocyten aantal. Prognostische factoren voor late resistentie waren hoog granulocyten 
aantal, grote lesies en primaire tumor lokalisatie buiten de maag. We veronderstellen dat 
het hemoglobinepeil het geneesmiddeltransport van het bloed tot de tumor kan 
beïnvloeden, dat de biologische werkwijze van tumorgroei kan verschillend zijn voor ziektes 
van verschillende primaire lokalisaties, en dat grote tumoren vaker secondaire genetische 
mutaties kunnen herbergen die zouden leiden tot recidiveren van de tumor. 
Vroege resistentie was onafhankelijk van de dagelijkse dosis imatinib, maar late resistentie 
was dosisafhankelijk, meestal in bepaalde prognostische subgroepen. Een verder 
onderzoek van genetische mutaties in de oorspronkelijke tumorblokken toonde belangrijke 
correlaties tussen de mutatietypen en de oorspronkelijke ziektelokalisatie. 
In Hoofdstuk 7 hebben we, gebaseerd op data van dezelfde studie, de patiënten 
karakteristieken geïdentificeerd die het optreden van de belangrijkste bijwerkingen 
beïnvloeden. Vrouwen en patiënten van gevorderde leeftijd of met een slechte klinische 
conditie hebben gewoonlijk meer kans op oedeem, huiduitslag, vermoeidheid, misselijkheid 
en/of diarree gedurende de behandeling met imatinib mesylaat, maar deze factoren geven 
niet dezelfde mate van kans op de verschillende bijwerkingen. Diarree is ook meer frequent 
bij patiënten met een tumor van gastrointestinale oorspong, huiduitslag bij patiënten met 
kleine letsels, en moeheid bij patiënten die eerder werden behandeld met chemotherapie. 
Alle bijwerkingen (uitgezonderd neutropenie) zijn geheel dosisafhankelijk  maar, ook hier is 
de invloed van de dosis is niet van dezelfde omvang op alle bijwerkingen. 
We hebben daarom multivariaat modellen ontworpen om de kans van alle bijwerkingen te 
schatten voor individuele patiënten. Deze ingewikkelde modellen zijn samengevoegd in een 
Excell programma dat gebruikt kan worden door de behandelend arts. Deze modellen 
werden gevalideerd met de data van de vroegere fase I / II studie van EORTC-STBSG met 
imatinib mesylaat. 
Toekomstperspectieven 
Op basis van de onderzoeken met de databank van de EORTC STBSG, zullen de studies 
beschreven in dit proefschrift bijdragen tot: 
Betere voorspelling van de uitkomst van beschikbare behandelingen voor vergevorderde 
weke delen sarcomen en GIST, op basis van patiënten en ziekte kenmerken voor de 
behandeling: 
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• Responskans en overlevensverwachting van patiënten die doxorubicine 
combinaties krijgen als eerste lijn behandeling voor vergevorderde ziekte. 
• Progressievrije percentage voor de patiënten behandeld met actieve en inactieve 
geneesmiddelen, na falen van eerste lijns behandeling, en voor verschillende 
histopathologische subtypes. 
• Vroege en late resistentie op imatinib mesylaat voor patiënten met vergevorderde 
GIST. 
• Inschatting van de belangrijkste bijwerkingen voor patiënten met vergevorderde 
GIST behandeld met imatinib mesylaat. 
Ontwikkeling of bevestigen van hypotheses die tot het begrip van deze ziektes zullen 
bijdragen: 
• Of levermetastasen van weke delen sarcomen relatief ongevoelig voor 
chemotherapie zijn, danwel een kenmerk van een vergevorderd ziektestadium zijn, 
buiten bereik van chemosensitiviteit. 
• Systemische chemotherapie is curatief voor een klein aantal patiënten met weke 
delen sarcomen. 
• Hemoglobine kan een belangrijke rol spelen bij het transport van imatinib mesylaat 
van het bloed naar de tumor. 
• De biologische tumorgroei in GIST is niet gelijk tussen de tumoren van 
verschillende primaire tumor localisaties. 
• Grote GIST lesies kunnen vaker secundaire mutaties veroorzaken. 
Optimalisatie van toekomstige klinische studie-opzet om nieuwe potentiële systemische 
geneesmiddelen te onderzoeken: 
• Studies die eerste lijns chemotherapie combinaties vergelijken zouden 
gestratifieerd moeten worden voor leeftijd, histologische tumorgraad en de 
aanwezigheid van levermetastasen. 
• Patiënten met laag gradige tumoren zouden niet geincludeerd moeten worden in 
studies die respons op behandeling als primaire eindpunt gebruiken. 
• RECIST geeft ons een gevalideerd primair eindpunt om celdodende 
geneesmiddelen te bestuderen.  
• Stabiele ziekte (progressievrije status) na 3 maanden is een gevalideerd eindpunt 
om celdelingremmende en doelgerichte geneesmiddelen te bestuderen bij weke 
delen sarcomen; referentiewaarden zijn nu beschikbaar voor dit eindpunt. 
• Referentiewaarden zijn ook verzameld om eerste lijn celdelingremmende en 
doelgerichte geneesmiddelen te bestuderen in fase II studies. De gunstige 
bijwerking profielen van deze nieuw medicijnen en de beperkte werkzaamheid van 
chemotherapie rechtvaardigen dergelijke studies. 
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In het eerste gedeelte van dit proefschrift hebben we onze aandacht gevestigd op patiënten 
die met eerste lijn doxorubicine combinaties behandeld worden voor vergevorderde weke 
delen sarcomen. Ifosfamide is het tweede actieve geneesmiddel voor deze ziekte, en 
gegevens van een groot aantal patiënten die met dit geneesmiddel behandeld zijn nu in 
onze gegevensbank beschikbaar. We zullen onderzoeken of prognostische factoren voor 
respons en overleving dezelfde zijn, dit om te helpen de beste eerste lijn behandeling voor 
toekomstige patiënten te kiezen. 
RECIST is zeker geen voldoende eindpunt voor screening van nieuwe doelgerichte 
geneesmiddelen in GIST. Progressievrije status na 3 maanden mag een geldig eindpunt 
zijn, maar we willen ook de huidige tumormetingen onderzoeken en bestuderen of zij meer 
betrouwbare en specifieke criteria kunnen leveren om vroege resistentie vast te stellen. 
Er werd aangetoond dat GIST resistentie op imatinib tegengewerkt kan worden door de 
dagelijkse dosis te verhogen; prognostische factoren voor eerste objectieve progressie 
mogen uiteindelijk de overleving niet beïnvloeden. Als genoeg follow-up beschikbaar is 
zullen we de prognostische factoren voor overleving karakterisere, en vergelijken met 
prognostische factoren voor vroege en late resistentie. 
We hebben prognostische factoren voor vroege en late resistentie in GIST tot op dit 
ogenblik nog niet gevalideerd, en prognostische factoren voor bijwerkingen alleen op basis 
van een kleine gegevensbank gevalideerd. Een tweede studie met imatinib bij GIST is , met 
een bijna identiek opzet, in VS en Canada uitgevoerd; we verwachten dat het mogelijk zal 
zijn de gegevens van deze tweede studie te gebruiken om onze modellen te bevestingen. 
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